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Ahs lrmcl
rhc invcstigutians reponed here highlight the cytotoxic effect of 3-Hydroxy-3-
mcthylglutaryl Coenzyme i\ (HMG·CoA) Reductase inhibition by tovasta tin on the
cultured human hepatoma cclilin c HepG2. This ir.vestigation focused on the toxic effects
of lovustatin at exposure levels at and above those currently used clinically, The
Inhoratory approaches used included electron microscopy, cell cycle analysis by (low
cytomctry. investigation of peripheral cell damage by enzyme leakage and other protein
studies, and analysis of intracellular and extracellular lipids for various exposure
concentrations and times. The experiments were also extended to consider the effects of
,llJding oleic ucld 10 the cell cultures as a nutritional supplement to enhance lipogenesis.
The findings arc discussed in light of current understanding on the significance of protein
preny lation on the cell cycle and the mechanisms of cell death by necrosis and apoptosis.
lh c lower lovastatin concer urati-ms used in this study (0.1 - 2.5 J.lM) did not kill cells,
even after exposure tor 8 days. However. if cell cultures containing otherwise nontoxic
lovnstatin concentrations were supplemented with oleic acidiBSA. cell viability was
signific:mtly reduced at all lovastatin concentrations (a=0.05). This work shows that
lovastatin supplemented by fatty acid can significa ntly affect HepG2 cell morphology and
functions. The results of this work suggest also that HcpG2 cells could be used as an
e ffic ient and practical model system to investigate the process of cell death in vivo. Also,
it is a convenient model for investigations on mevalonate-dependent cellular rncchcnisms.
This study providesevidence to support the potential rotcof lovastaiin trecuncm in cancer
managemen t.
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CHAPT ER I
INTRO DUCTION
The m ajor ca use of deat h and disab ility in western countries is atherosc lerotic he art
diseas e (Gotto CI at.. 1( 90). Iherc a rc several reaso ns for th is hib:h in cidence of
atherosc lerotic heart disease (Turley and Dietsch y. IIJR2) hut hyp crtipoprot cincrniu is
pred ominant. In the aqueous enviro nment o f the sys temic cir culation cholesterol.
trineylglycer o ls and phospholipids arc so lubilized in complex with upolipoprotcin 10 to nn
part icles kno wn as lipoproteins. There are many different types o r npolipo p rotcins. the
maj or ones b eing epo-A t, ape-A ll. upo-C l, upo-C lt. upo-C fH, apo- B mill upo - E, Eac h of'
the five diff erent major species of lipo protein particles in humnn blood h ave specifi c
upo fipoprotc ins associated with them. Apo-B, for example, is found in very- low-densit y-
lipoprotein (V LDL) and low-de nsity-lipo protein ( LDLl w hile ape-A t is charueterisric of
high-density -l ipoprolein (HDL) (Yang et ul., 1986: Knott cr nl., 1986).
Several epidemiological s tudies have confi rmed hig her risk fo r henri d isease in the
presence of hypercholesterolemi a (Lange r et ul., 1972). This is e specially true in the
prese nce of increased LDL-assoc iated cho lestero l. Treatment directe d at reducing LDL·
cho lesterol ha s been shown to lo wer the risk for iscbacmic heart disease (Avoge ro ct al..
1979; Sniderman et al., 1980; Waters et ul., 1995).
t. l Prope rt ies of 3~Hydroxy·3-Mcthylglutaryl.Coe"zyme A Itcdutla~e Inhibiton
In both the liver and the peripheral tissues. c holesterol inhibits its uwn e ndogen o us
synthesis by a classic negative feedback mechanism. The commiuc d step in cholesterol
synthesis and the foc us of nega tive feedback control is the enzyme 3-hydroxy -3-
mcthylgl utary l-CoA reductase ( HMG·CoA reductase) (Sirt cri. 1993; Oates and Wood,
19&8). lmportant weapcns in the pharmacological arsenal against hypercholesterole mi a
lire the mevinie acid derivatives (vastarirrs) show n in Figure 1.1 (Robisnc et al., 1994;
Blum . 1994). Thesecompounds netas specific inhibitors of HMG·CoA redu ctase, The
ration ale behind this mode of treatment is that if hepatic endogenous synthesis of
cholesterol is blocked. the liver will be starved for cholesterol needed fo r its own
metabolic purposes (mainly synthesis of bile sa lts). The response of the liver is to
scave nge cho lesterol from the circulation (Sirto ri, 1993). This has been shown to
dramatically reduce the level of total cholestero l in the blood and, pe rhaps more
impo rtant, to reduce the level of LDL part icles (Tobert, 1987; Fobert, 1988 ; Alberts .
1988; Hunninghake, 1988; Shepherd, 1995 ; Corsini er nl., 1995; Hsu et at., 1995). T he
inhibition of cholesterol synthesis byvastatlns has beendemonstrated in vitroin a number
of animals and human cultured cells line and, in vivo in several anima l speci es (Chao et
ul., 199 1; Corsini et al .. 1995).
The che micalst ructures of thefou r available HMG-CoA reductase inh ibitors are
shown in Figure 1.1. Lovastatin is a natural product of Aspergillus te rreus(A lberts et al.,
1980 ; Alberts. 1988; Corsini ct al., 1995); and simvastetin and pravastatin are produced
hy chemica l modification of the parent Iovestatin molecule (Serajuddin et al., 1991) ,
These three compounds havea hydronaphthalene ring that interacts with the coenzyme
~HO ~O~O 0H,C # #
lo vastatin
Pravastatin
l6HO .0~O 0Hie U ~
Simvastatin
0- "-
Flwa51atin
Fig.1.1. Chemical structures of
methylg1utaryl-coenzyme A dcurrent lY ava ilable
re uctase inhibitors.
3-hydroxy·J·
A recognition si te of BMG-CoA reductase (Alberts , 1988). Additiona lly, they have a
hydroxy -acid sid e chain that mimics mevalonate. F luvastatin, the first totally sy nthetic
IlMG-CoA reduc tase inhib itor [Kathawafa, 1991: T se eI a l., 1990: T sa et 011.. 1990:
Rubisno ct al., 1994), has a structure that is distinc t from thai of the fungal p roducts.
Huvasta tin is a m evalono lactonc deri vative o f a Iluorc pbeeyl substituted indole r ing. The
Iluerophenyl ind o le port ion of Iluvas tatinmimics coe nzyme A in interacting with HMO-
CoA red uctase an d the side chain mimics m evalonat e (Keilso n et al., 1990).
Lovastarin and si mvastetin are pro vided as inactiv e lactones that m ust be
hydrolysed to the correspon ding Bchydrcxy a cids for pharma col ogicactiv ity tSmit h, 199\ ;
Halpin c t al., 19 93). Th us tbey are prodrugs . I'ravast atinand lluvastati n nrcpro vided in
tl...i r act ive hydro xy acid forms.
F luvastatin . which is chemical ly synthesized , is racemic. with eq ual am o unts of
tile high ly ecuve (J R. 55) and we akly active (SR. 35) enantiomers. T he high ly active
cnentiom cr of Fluvasa tin has more than30 t imes the potenc y of the w eakly act ive one
(Kahawala, 199 1). Because funga l meeb o lu es areb iosynthesized. they contain onlyan
uctivcena ntiomer.
1.2 Lc vsstann TOll.icity
Lovastatin toxici ty has bee n studie d in no n-primate species. particularl y rats,
rabbits. and d ogs{Chao ct .:101.• 1991: Cors ini ~1 al.; 19Q5l. II appears that high dtlllCS o f
lcvasta un.on a long-te rm basis. canaffect themorp holO(;ica l fcnurcs of rodent liver (d is .
Foci of cellu lar altera tion appear eithe r as baso philic o r eosinophilic areas ;md m e
randomly distributed th roughout lhe liver lobule. 1I)'J~..rp lusia ll( hepalic hilc d ll;l5 h as
been alsoobserved T hesechanges occu r reproducibly in r.lts fKl t llnly lifte r In:...tmc m
with lovastarin but also with several othe r HMG·ClIAred uctaseinhibitorsof s imi!;lr and
differ ing struc turesand the responseis de pendent on dos..' ge and CXIXlSUn:: time (the IIU-
effec t dose for the appearance of these changes in long-term stud ies is 5 mg/liwday)
(M ac fjo nald et 31.. 1988). Nos imilar cha ngeswere reported indogs. mhhils or monkeys.
Theabov elindin gsarcnOIconside redto be important fOl' human safety evnluatio n.
Central 10th is conclus ion is the fx t that rodents respond to inhibition of I IM(j·Co A
reductase in a manner distinct fromdogs andhum ans{llalpin el al., 1911l ). In response
to inh ibition of the e nzyme. these species exh ibit marked induction of I IMO,CoA
reductase sufficient to prc~nt sustained deceases in seru m ehulcsn..-roI conccmrario ns
(Bensch et at .. 1918; Endo ct at , 1979: Fears er al., 1( 80). This intense enzyme
inductionocc urs predominantly in the peri portal re gionsof the liver lobule (Sinb'l.'f er ul.,
1984) which is coincid ent with the atypica l cellular areasiden tified h istologically . Stud ies
by Singer (Singer et at , 1984; Singe r cl al., 1988) have demonstrated that lhc se
patho logical areas have extensive proliferation of smooth endoplasmic ret iculum, the
mem brane in which IIMG·CoA reductase is bound . It is thi s membrane proli fcrationthat
is rc cllb'tli7..able at the liJ;htmicroscopic level as c ellular a tYPia.
II dos e of2oo mg.r\glday of lova statin ad rninis ered for6 months to r a ts produ eed
a sig n ific:mt m orpholo g ic changes in the livtt but cosdministratlo n o f mevalo nic acid (t he
product of th e inhibi ted enzyme) had a pronou nced pro tective e ffect. Liven of rats
treated with tovesaun and me valonic acid sim u ltaneous ly could not be di stinguished
from control tlssue. Th ese data demons trated tha t for rodent liver, while the mechani sm
of induction of foci of cellular alteration was not known. the patho logy is cl e arly related
\0 inhibition of mevalonere synthesis.
High d oses of lovasrarin and oth e r HMG-CoA reductase inhibitors we re rapidly
lethal in rabb its, Preli minary data indica ted that h igh plasma levels of these compoun ds
were observe d at co mpamble dosage le vels in dogs (MacDo nald d al., 1988) were
achie ved in th ese speci es. The rabbit is uniquely sensitive to Iovastatin. The proba b le
eause of deat h in rab bits receiving hig h dosage levels o f lovastatin was ccntrilobular
hepatocellular- necrosis (Kombrus t el al., 1989). This occu rs ina do se-depend ent fash io n.
Increasing degreesof h epatic dam age ar e observed as the do se is inc reased from 100 to
200 m glkgfda y . As fo r rats, co- ndministrarionof mevnlonate with a frankly hepatotoxic
dose of lovas tmin com p letely prevents her-aile damage. Studies repo rted by Kornbrust
(Korn brustet al., 1989) indicated that th is preventio n was n ot simp ly dueto inhibition of
drug uptake in the liver: similar concentrations of drug in the liver were observed w ith
or witho ut mevalonate co -administratio n.
In auditio n. data are available 10 show thai co -udminisrmrion o f mcvnlouarc can
reverse hepatic d amage in rabbits even after it is allowed to pro gress lo r approximately
4 to 5 days (Kornbrust et a l., [989). These findings c1ear[ydcmunstmtc that the observed
toxicity in this species is related 10 marked and sustained inhibition of mcvnlunutc
synthes is.
Exposure of culture d cellsto lovastatin not onl y blocksmevalonicacid production,
thereby inhibiting choleste rol synthesis. but also prevents DNA replication lind cell cycle
progress ion (Hab enicht e t 0.1., 1980 ; Fairbank 0.1.. 19 84: Ortiz c t 0.1., 19(5) . As both of
these phenomena are reve rs ible with an exogenous supply of m cvulcnutc {Gol dstein ;Iud
Browen , 1990; S epp-Lorenzine et (II.. 1991), it would appear that the mechani sm for
lovnstatin -induced interfer en ce with DNA replication an d the cell cycle invo lve depletion
ormevetonare o r its metabolites (S umi et al., 1992; Sumi cr al., 1994).
Using this general method of exploring the pathogen esis of o bserved changes
(supplem entation with the product of the enzyme inh ibit ed), it ha s been possible til show
that many of the effects produced by lovastaiin and o ther HMG -CoA reductase inhibitors
were a d irect result of inhibition o f mevalonate synthesis. In ad dition to the findings on
the preve ntion of lo vastatin -m duced liver dam age in ra ts and rode nts with mcvalnnic acid,
this substance is also effective in preventingthe slight increases in serum transaminase
activity observed in dogs undergoing experimental administration of lovastatin.
Mcvulunate also pre vents the renal and gallbladder changesobserved in rabbits receiving
highdosage levels of tovastann [ Kombrust er at, 19 89).
Another characteristic feature of HMO-CoA reductase inhibitor toxicity is a
hyperplastic change in the squamous epithelium of the nonglandular stomach of the rat
(acanthosis). Hyp erplasia in this unique anatomicstructure(not present in humans) has
been shown to be related to inhibition of mevalonatesynthesis as it can be induced by a
wide range of HMG-CoA reductaseinhibitors of varying structure (14 compounds have
been investigated), theeffect is antagonized by co-ed ministruricn of mcvnlonute, and is
not produced by pharmacologically-inactive epimeres o f potent inhibitors (MacDonald er
a1..1988)
1.3 Acute Lov asuue To:.icity in Humans
The general conclusion extrapolatedfrom the non-human studies reported above
is probably that the dosage regime required to induce clinically-significant lowering of
blood LDL-cholesterollevels inhumans is belowthe tox icity threshold. However, clinical
studiesdiscussed be low demonstrate that the effectof lovastatin in humans is not entirely
benign.
Small increas es in serum tra nsaminase s. ~'\rticul3l'l)' in ];lulam ic l'I)'m vic
transaminase (alanine transaminase], so metimes occu r. e tt en within 6 wee ks or start ing
therapy [l.ovastatin Study Gro up 11. 1986 : Havel er al., 1987 ; Lovastatin Stud y Group III.
1988 and Ill ingwort h ct al., 1988). Suc h increases art: c ncn tra nsient and have nol
necessitatedw ithdraw al of thera py. The samephenomenon has bee n l\'JlOrlo..-dwilh lllu~1
other lipid-lowering dru GS ( Brown and Goldste in. 1( 85) . In a large clinical triill
compari ng lovastatin and chotestyramine (Lovnstatin Study Group III. 11)1\8). hlllh dru~s
raised transamina se lev els equally (Hunnlnghake. 1988). Because cholcsiymmineis lI t1t
absorbed from the gas trointes tinal tract. small Increases in trnnsummnscs may he lin
indirect respo nse to cha nges in lipid metabolism.rather than a direx t effect on the liver.
A more important finding is that 1.9% o f the patie nts trea te'11 with lovastatin in clinical
trials have had asym ptomatic but marked and persi s tent transaminase increase....
particularly serum glu ta mic pyru vic transami nase (Tobcrt, 1987; Mc vecor. 1988; 'robert,
1988; Sirtori. 1993). V/hen the drug WlIS disco ntinued . transam inases rctllffil.."l.I tn
pretreat ment leve ls. usua lly wit hin a few weeks. In contrast 10 the small increases in
transaminases that appear early in theropy, larger increases have usuall y occurred bet wee n
3 and 12 months afte r stlll1ing therapy. Thi s side eITL'Ct is clearly related to the dose of
the dru g. In the 48-w eek EXCEL study (Expanded Clinic al Bvatucrlc n of Lovestarln ).
persiste nt transaminase elevation of > 3 times nor mal was found in 0,1% of perso ns
treated wlth 20 mg daily; in 0.9% of persons treated with 40 mg daily and in 1.5% of
persons given 80 mg d aily [Dujovne ct al., 1991). To date. no pe rmanent liver damage
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has been documented w ith lovastatin. A lkaline phosph atase remained essent ially norma l,
indicating that the effe c t is mo st probably hepatocellular ra ther than cholestatic . All the
patiel1tswho ha ve had increased transamina se levels have been asym ptomatic througho ut.
1.4 Long-term Lcvastarin Toxicity in Patients.
Must of the lo ng- term d ata on lo vasratin ha s been provided by a collec tive stud y
of pat ients who participated in the original four mu lt icenter controlled studies {Lovastatin
Study Group 11, 1986 ; Havel et ul.. 1987; Lova stntin Study G roup Ill , 1988 and
Lovcsreun Stud y Grou p IV, 19 88). In study by Tobert ( 1988) 744 patient s had been
tnkin g lovnstat in for an average of 2.5 years. Along with lo vastarin, approximately half
uf these severel y-hypercholeste rolemic patients were taking other l ipid-lowering agents,
usually resins. at some point du ring thei r therapy. Therap y for 15 patients (2.0%) was
discontinued because of drug-a ttributab le adverse events. Thera py for mo st of these
patien ts was di scontinu ed because of pers istent asy mptomatic increases in t ransaminase
levels to J t imes the upper limit of norma l. In an EXC EL study, the perc entage of
indiv iduals a ffected was dose d ependent, increasing from 0 . 1% at 20 rng lovastat in I day
to 1.5% on 80 mg/dny (Bradford et el., 1991; Duj ovne et a l., 199 1).
In conc lusion. th e clinical trials ind icate tha t there is no evide nce of adv erse event s
appea ring afte r prolonged use . The dr ug-attribut able discont inua t ion rate is low and
demo nstrates the Good to lerabilit y and adverse-effect pattern of the drug at the dosage
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levels employed for therapeutic lowering of LDL-ch~l1csh:ro1.
1.5 The UEPG2 Cell Line.
The HcpG2 cell line was established in. 1979 rromminced human hcpatoblasuuun
tissues that were initially overlaid 011 feeder cultures of irradiated 1l111IlSC cells. "ncr
several months of passage. a feeder-independent proliferatingcellline wasobtained[Aden
et at, 1979: Knowles t:1 al., 1980).
Many investigations on hepatic lipoprotein metabolism have used IIepG2 cells
(Ellsworth et aI., 1986; Dashti and Woltbauer, 1987: Dushu c t al.. 19lN). This human
hepatob lastomu derived ce ll line expresses many of the functions of normul human
hepatocytes (Grant et al., 1988; Silversct al., 1994). It has been welldocumente d that
thiscetl Iinecan synthesize and secrete lipoprotein fractions within the density ranges of
VLDL. LDL and HDL (Is hak and Glunz, 1966: and Ellsworth ct u., 1I,lH6). They have
alsobeen shown to secrete theapolipoproteins B, E, AI. All, A IV,C II and CIII. The cell
line has been used as a model system to study lipoprotein synthesis ami metabolism
(Moberly ct ul., 1990; Cian tlone et nl., 1992; Dixon and Ginsberg. 1(93). ApI) ll- IOO,
the sole ape B species secreted by the human liver, is ulso the on ly upo B species
synthesized and secreted by the HepG2 celt line (Furukawa ct al., 1992; Ctanflonc ct ul.,
1992 and Dixon and Ginsberg, 1993). However, although HcpG2 cells cansynthesizeand
secrete lipoproteins in the VLDL and LDL ranges, it appears thai the armn containing
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lipoproteins that arc secreted have the buoyancy of LDL rather than VLDL. The particle
size and shape Ill' apo B containing particles have been found to be similar in both size
and morphology to that of plasma LDL (Javitt. 1990).
IlcpG2 cells have also been shown to synthesize bile acid (Javit t. 1990; Axelson
cL al.• 11)91: Cooper ct OIL. 1994) and many liver-specific proteins (Knowles ct nl.. 1980).
lIep(j2 cells maintained only in Eagle Minimum Essential Medium will continue to
synthesize cholesterol (Javht. 1990). Vastatins effectively inhibit cholesterol synthesis in
IlcpG2 cell (Chao ct u!.. 1991) and experimental evidence suggests that they also interfere
with intracellular cholesterol esterification by reducing the activity of ACAT (Cianflone
ct ul., 11)1)0: Corsini ct <II.. 1995).
Ihc lipid composition of HepG2 cells grown 10 confluence in serum-containing
medium has recently been compared to that of human liver (Wang er at.. 1988). HepG2
total lipid courer n(255lJgfmg protein) was much higher than that of normal liver tissue
(1.J3Jlgfmg protein). The increased total lipid content of HepG2 cells was the result of
nn elevated triacy lglycerol and phospholipid content. whereas the cholesterol content was
comparable to that of human liver (Juvitt, 1990). Cholesterol or cholesterol esters nrc
available in HepG2 cells in quantities adequate to support apo 8 secretion at most levels
of tritlcyll,!lyc rol synthesis (Dixon and Ginsberg, 199]) . The ava ilability of cholestero l
nr cholesterol ester may only be rate limhing under certain conditions. The effects of
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delivery of lipoprotein cholesterol esters to l-kp01 cells may depend on the status 111'
cholesterol metabolism in the cells and on the particular lipoprotein used. Although these
comparisons did not take into account the filct that norma l human liver conmlns lilur
major cell types; parenchymal. endothelial.kupflur and stellate cells: they .111 indicate that
1-lep0 2 cells. although a rapidly growing cell line. ure not trincylgtyccrol or phospholipid
poor (Dixon and Ginsberg, 1993).
lt must always be remembered that 1-lep0 2 cells lire an inuuo rtaltzcd cell line ,111([
there could be many differences between these cells and human hepatm:YI\!s ill vivo.
Therefore. many of the results obtained with 1-lcp02 cells should he corroborated in
primary cultures of humanhepatocytcs. being careful to ensure that the culture conditions
tire adequate to maintainthe continued transcription of liver-specific genes and to prevent
the dedifferentiation of these cells in culture (Jefferson et al.• 1911 5: Clayton ct al., 191(5).
1.6 Toxicity Studies using the IIcpG2 Cell Line.
lnvuro cellular models have been proven to be extremely useful in some areas of
toxicology research because the mechanism of action of potemlully toxic chemicals and
drugs and their metabolism CM be studied under strictly controlled conditions (Acnstu et
01.. 1985; Ball et al., 1995). The organ-specific or basal acute toxic effect s oruparticular
compound can be assessed with the combination of metabolically competent cells from
the target organ in parallel with non-differentiated cell lines. The spccies-spccilic effecl
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of'u chemical can also be easily evaluated by using in vitro cellular systems from different
species IEkwull and Ekwall. 1988). In vitro cytotoxicity data provide a relat ively quick
and inexpensive way of ranking chemicals according to their potential toxicity (Ekwall
ct <11.. 1988; Ekwall et al.• 1989).
I" vitro cytotoxicity assays can also reduce the usc of Jive animals for toxicity
testing of chemicals such as newly developed drugs; a procedure which is expensive and
ethically controversial. However. the relevance and reliability of in vitro systems for
predicting toxicity in humans have not been adequately evaluated. The validation of ill
vitrn assays is the key step 10 increase the use of in vitro methods to complement or
replace ill vil '/1 testing. Recently, validation stn tegics have been proposed and d iscussed
as part of several programmes to assessing the relevance and reliability in vitro
toxicological methods [Ekwall et al.. 1991), In. 1989. the Scandinavian Society of Cell
Toxicology started n multicentre evaluation of ill vitro cytotoxicity (the MEIC
programme), whose main purpose was to the correlate results from a substantial number
ori n vitro experimental toxicity nssay methods with human toxicity data (Bondesson et
:11., 1989),
The liver is frequently the target organ of toxic chemicals because the hepatic
biouctivurion of xcnobiotics may generate metabolites that are more toxic than the
orig inally administered compound (Okey et ai., 1986). Since xenobiotic biotransformation
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may differ significantly from one species 10 another (Hucker. 1Q70: Quinn c'1 al., 19$11;
Tee et 'II.. 1981). cultured human hepatocytes. which retain most liver- specifi c funclillniC.
represent an acceptable simplified model for prl.-dictint; the ill ri l" hl.'fl'U\ltllxicitr nud
metabolism of new drugs in humans. Thead\"nlliage of c-uhurcd human hl'''P'lIIlCYlc-s I~s
been shown in a study by rever ct al. {I99:!) who demonstrated Ihal the acute Il1xicity III
humans of the first ten MEIC chemicals was 110 n: accu r:ucly predicted llsinl; human
hepatccytes than using rat hepatocytes or mouse non-hepatic 3T3 cells.
Cultured cells of the human he patoblustomn-dc rivcd line IIcpG2 display
morphology and function similar to tha t of liver parenchymal cclh ill \'iI 'o including the
production of the m3jor bloodserum proteins. UepG2 cells also retaindrug-rnclalxlli..j ng
capabilities. including the cytochrome P45Q..dcpendcnt mixed function oxidascs and
glucuronic acid and sulfate-conjugating activities (Silvers ct OIl. 11)1)4 ). Being a
permanent, stable cell line; drug metabolizing ectivities should nul diminish in culture as
happens with primary cultures of human hepat ccytc s [Grant ct ul., ICJ88; Forrester cr nl.,
1992: Gugen-Guillouzo er ul., 1988). It .....as shown that tho= culture medium composition
can affect drug metabolising enzyme activities of the IIcpG2 cell line (Doostdar cl al.,
1988). Due to these chamcreristlcs, HcpG2 cells nrc widely used as an in vilm model Ilf
human hepatocytes for studies of envhonmental carcinogen nctivatlon [Liu cl al., IIJIJ) ),
chemical rnutngenicity(Silvers et ul., 1994) and drug metabolism and cytotoxicity (Duthie
and Grant, 1989; Hall cr nl., 1991; Hall ct ul., 1993; via u ct ul.• 1993; Babich el al.•
16
1( 93). 1-lcllG2 cel ls have also been used in cytotoxici ty and genotoxici ty investigation
of environmental po llution and have been suggested as a convenient and sensitive model
ror screening comp lex pollutant mixtu res (Naji -Ali ct al., 1994; Duthie er at . 1994),
I IcpG 2 cel l line retains many morph ological and biochemica l cha racterist ics ofn onnal
human hepatocytcs(Ade n cr al., 1979; Bouma et al.. 1( 89), It has been extensively used
10 study hepatic funct ion, including cholesterol. lipoprotein and bile acid metabolis m
(Javitt, 1990; Thrift et ul., 1992: R N; Cooper et al., 1994). Other studies with cultured
IlcpG2 cells (Ellswo rth ct al., 1986; Cian llone et a!.. 1990; Dashtiet al., 1989) have used
supp lement atio n with oleic acid to promote lipogenes is and VLDL secre tion. In the
prese nc..: of oleate, lovastatin reduced apoB secret ion. diminished cho lestero l ester
synthesis, but did not affect triglycerid e formation (Cia nflcne et al., 1990), Howeve r,
these effec ts of lovnstatin on apoB secreti on were not seen in the absen ce of oleate
(Pollinger ct al., 1989. Cian flone, 19(0). These results in vitro observat ion appear to
comp leme nt the in vivo observat ions (Ar ad et ul.. 1(90). HepG2 was found by treatm ent
o f lovnstatin to coord inate ly regulate the exp ression of LDL receptor, HMG-COA
reductase and I-IMG-COA syn thase (Mclowa and Cimis, 1989).
1.7 Detection of Ce ll Death
Cell death. the irreve rsible loss of vital ce llular structure, can take p lace by either
of two me chanisms, necros is or apoptos is (Wy llie, 1981; Ledda-Col umbano et al.• 1991 ;
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Majne and Joris, 1995). While cells undergoing necrosis or aPl-lptnsis can readily he
dist inguished morphologically, the underlying molecular mechanisms are incompletely
understood (Uchiyama. 1995).
Necrosis is recognized by cellular metabolic collapse and acute cellula- il~iury: and
occ urs when a cell no longer maintains ionic homeostasis. As ATI' levels be come
exhausted and transmembrane ion gmdlcnrs ure dissipated, the celt swells and internal
organelles become distended (Wyllie, 19lH: Uchiyama. 19( 5). t\ t a critical point the cell
membrane ruptures and spills om lysosomal enzymes which mediate non-specific
inflammation in the surrounding tissue. Necrosis is typically induced hy extracellular
trauma such as hypoxia, membrane-act ive toxicants, and respiratory puisons such ,IS
cya nide. When viewed by light microscopy. cells undergoing necrosis demonstrate
uniform eosinophilic staining of the cytoplasm and substantially normal staining Ill"the
nucleus (Uch iyama, 1995). Some nuclei show hypcr chrom atiuisrn without shrinkage (If
complete dissolution (Wyllie. 1981).
The term apoptosis describes a phenomenon traditionally interpreted as
prog rammed cell death (Kerr et nt.. 1972) which is characterized by controlled
autodigestion of the cell. In vlvo, npoptctic cells lose contact with their neighbours as
they decrease in size; they exhibit chromatin condensation: and plasma membranes
undergo a characteristic pathological extrusion-generation known as "blcbblng'' (Amenta
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ct el., 1993; Majno and loris, 1995). Apoptosis also involves characterist ic changes
within the nucleus. The nucleus undergoes condensation as endonucleases are activated
und begin to degrade nuclear DNA. In many cell types. DNA is degraded into fragments
the size of o ligonuclcoscmcs, whereas in others larger fragments are produced. Apoptosis
is also characterized by a 10·(Sof mitochondrial function. This has led to speculatio n that
mitochondria may have an important function in regulating apoptosis (Vayssiere et al.,
1994; Rcipcrt et al.. 1995). While the dying cells maintain their gross plasma membrane
integrity, subtle plasma membrane changes signal neighbouring phagocytic cells to engulf
them and thus complete the degradation process (Ellis et ul., 1991; Uchiyama, 1995).
Cells undergoing apcptosis that are not immediately phagocytosed disintegrate into smaller
membrane-bound fragments called apoptotic bodies . An important fea ture of apoptosis
is that it results in the elimination of the dying cell without induction of an inflamma tory
response. In contrast. necrotic cell death is associated with an early loss of cell membrane
integrity which results in leakage of cytoplasmic contents and the induction of an
inllmnmatory response (Mejno and l oris, 1995).
It has been shown (Reedquist, et ul., 1995) that high concentrations of lovastatin
can inhibit ce ll proliferation and differentiation in lipopolysaccharide-activated murine B
lymphocytes. perhaps through induction of programmed cell death (apoptosis). Also.
treatment of human malignant glioma cells with a lovastatin concentration as low as 10
mM over a period of n hours led to DNA degradation into nuclcosome-sized fragments
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characteristic of apoptosis (Jones er al.. 1994 ). The cell cycle of a human bladder
carcinom a T24 cellline was arrested in G1 phase (an indication of apoptosiS) :ll 10 ~1~-1
lovastatin [Jakobislsak et ai., 1991). Morphologica l changes typical for upoptosis W,IS
confirmed afte r 72 hours of exposing a human prosta te cance r cell line, [l (, . ) , hi I() ~I M
lovastatin (Borner et al., [995) .
Seve ral methods have been employed to assess lovustmin-ind uccd IlcpG::! cell
dea th and cyto toxicity by lovasratin. Somc invol ve detection of increased membrane
permeab ility; such as trypan blue uptake. a characteristic feature of dead cells: plasma
mem brane lactate dehydrogenase (LD H) leakage through the plasma memb rane: o r
sulfo rhodami ne 13 (SRB ) binding to unicnchcd lmreccllulnr proteins . so providing an
indicator o f relative protein leaching. Ot her cytotoxicity assays measure functional aspects
of living but not dead cells (Rubinstein et al., 1990). Thus. the tctrnznliurn dye M'!'T is
converted into its insoluble fo rmazan derivative by active mitochondrial cJehydmgenasc;
lind uptake of neutral red into lysosomes is ev idence of cell viabi lity; both exclusive
properties o f living cells (Keepers cr al., 1991). Whilst it is relati vely easy til determine
by any of these methods whethe r necrosis has taken place. it is unclear whether they nre
relia ble determinants of apoptos is.
Sclp hc rhodaminc (SRB) is a sulfonated aminoxunthcnc dye with histochemical
properties similar to that of related dyes such as Coomasslc brilliant blue, hromophenol
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blue anti naph thol yellow S, which are used widely as protein stains. Under mildly acidi c
conditions, SRB binds to basic amino acid residues of protcins in TCA-fixed cells to
provide a sensitive index of cellular protein content that is linear over a cell density range
of at least 2 orders of mag nitude (S kehan et al., 1990). The protein-bound stain can be
solubilized under alkaline conditions and the op tical density of the solution used to
determine relative cell grow th or viability in cu ltured cells (Keepers et al., 1991). Colour
development in the SRB assay is rapid, stable and visible.
Electron microscopy (Wyll ie, 1980; Beaver and Waring, 1994 ; Uchiyama, 1995)
permits clear ide ntification of apoptotic cells on the basis of the characte ristic morphology
out lined above (Sonc and Wick, 1994).
Flow cy tometry. using propidium iodide as a fluorescence DNA stain, permits cell
subpopulatio ns 10 be identified. Apoptotic cells can be recognized on the basis of a ' low
subdlplold peak'; that is the presence of cells having DNA contents less than typical of
normal cells in 0 1 transition (low subdiploid peak) (Gorczyca et al., 199] ; Zaleskis ct al.,
1994; Aten er al., 1995). Flow cytometric analysis is a very rapid and objective way of
ljuantifying apopto tic cells in a mixed populat ion. Flow cytcmetry with prcpidiurn iodide
is the qu ickest and most efficient method for measuring apoptosis and is particular ly
suitable for large-scale in vitro studies (Sene and Wick, 1994).
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t .8 Aim uf the Work
This work aimsat studying rhecytotoxicity and metabolism of'lnvastaun \\1vllri\ll1s
conccnrrctions on human cultured hepatic cells. l-kpG:! cells has been chosen I'i,lr the
provensimilarity of their metabolic pathways10 those: of human hepntocytcs. Since the
primary target organ for inhibition of cholesterol synthesis and metabolism is the liver
it is important to study lovastatin cytotoxicity with a human liver cell line. [loth acute
.'Old chronic effects of lovestatin are reported.
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CHAPTER 2
MATERIALS AND METHODS
23
2.1 ~bleriliis
HepG2 cells were obtained from the American Tis.''I1I: Culture CllllL-.;!;on
(Rockville. MOl. Tissue culture medium.fetal calf serum. delipidatcd fetalcalf serum.
trypsin. irypane blue and other tissue culture supplies were oblainl.'d nom <iih.·o
(Gaithersburg. MD). Tissue culture flasks and multiplatc-wells were purchased from
Falcon (Cockeysville. MOl . ( I~CJ-Oh:ic ad d WOlJlpurchased from DUP'\nt-New Ellghmd
Nuclear [Mississauga, Ontario). Oleic acid (sodium salt). nitty acid-free bovine serum
albumin Fraction V (BSA) . o-phthulaldehyde. pmpidium iodide. sulforhodarnlne n lind
nilother reagents were obtained fromSigmaChemical Co.• (St. Louis, USA) . I.DII. AST
and AL T slides were supplied by Kodak Ektachem Clinical Chemistry Co. (Rochester.
NY), N-methyl·N-trimethylsityltrifluoroacelamidc (MSTfA ) fcr dcrivctizmionwas from
Pierce (Rockville.I L), The Apo A and Apo B kits were from Orion Diganostica CE.. ...."").
Finland). Lcvastatin was generously provided by Merck. Sharp nrxl Dohmc Research
Pharmaceuticals (Rahway. NI).
2.2 Method s
2.2.1 Cr llCullurn
HepG2 cells were grown in Falcon tissue culture T-25 flasks in 5.0 mL uf Ellgle
Minimal Essential Medium supplemented with 10% fetal calf serum and O.! mM nun-
essential amino acid mixture. ImM sodium pyruvate. 1O.()()O unit:Jml. penicillin!
streptomycin (Furukawa et aI., 1992). The celts were grown at 37°C under II humirJilicd
2.
atmosphere of 95% air, 5% CO2, The cell medium was replaced on the third day. By
Jay 5-6 each flask reached almost 80% confluency and the cells were sub-cultured as
follows:
[he growth medium was removed and the adherent cells were washed once with
Cal' free Mg~ ' free phosphate buffer (CMF-PBS). The cells were detached by treatment
with 3 mL of eMF -PBS containing 0.25% trypsin solution for 5-10 min at room
temperature. Detached cells were suspended by gentle pipetting and 2 mL complete
medium was added as substrate for residual tryptic activity to counter over-trypsinization
of the cells. The cells were transferred from the culture flasks to capped conical
centrifuge tubes which were cent rifuged at 1000 to 1200 rpm for 5 min. The cell
suspension was mixed vigorously with complete medium. Cell viability and number was
measured by exclusion of trypan blue (0.04% solution). The cell viability was 90-95%
nil.each day of culture. The desired volume of fresh complete medium was added and
cells were resuspended gently by pipetting up and down. The cultures were diluted ]-fold
every 5-6 days.
2.2.2 Acute and Chronic Treatment with Lovastatin
I X 106 HepG2 cells/well incom plete medium were added to flat bottom 24- well
plates and left overnight to ensure adherence. For all following treatments cells were
cultured in complete medium except that 5% dclipidated calf serum was used in place of
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10% fetal calf serum. AI Day O.lovastatin. oleic ad dlBSt\ complex. lcvastatin and oleic
acid/BSA. or medium alone ' ·..as added to the cells. ln all cultures where !lleic acillll1SA
was added. either alone or with lovastatin. the final concentration oroleic add was lUI
mM and the treatment time was 24 hours. In case of loousnuin alone. the concc nuuuon
ranged from 0.1 to I00 ~lM. lind the treatment time I·R days. with medium change cvcrv
2 days. HepG2 cell morphology was assessed every two days hy phase microsco py ;11111
electron microscopy.
2.2.3 Levnsmtin pr epar atio n nnd ndrntnlstru tion,
Lovastatin was generously provided by Merck Sharp und Dohmc Research
Laboratories. Rahway, New Jersey. A 5 mM stock solution was prepared in iso prnpanlll
and stored frozen. An appropriate volume of stock solution was added 10 culture medium
con taining HepG2 cells to produce the desired lovastatin concentration in 11 final
co ncentration of isopropanol not exceeding 0.01%. Control cultures were grown with
isopropanol alone (Cianflone er 31.. 1990 ).
2.2.4 Preparat ion or oleic acid/bovi ne serum albu mm compie:".
Sodium oleate (40 rng) was dissolved with gentle heating in S.Oml, nfn .I)'y"Nile!.
Delipidatcd bovine serum albumin (SSA) was used. The purity nflhe fatty acid and USA
was verified by thin layer chromatography <TLC). The oleic acidl13SA complex was
prepared as described by Van Harken et al. ( 1969): 1.0 g of defatted nS A W;IS dissolved
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in 5. 0 mL of 0.9% NaC!, the pH of the solution W:lS adjusted to 7.4 and the solution was
placed on icc. The pll adjust me nt was critical for the formation of stable, op tically clea r
fatty <IcilllBSA complexes. The wurrn fatl y acid solution was added to the co ld albumin
sulu t ion, and the mixture was stir red well overnig ht at room tempera ture. T he complex
was s terilized by passage through a 0.45 11m filter and stored at room temperat ure. The
ratio of oleic acid to albumin after ste rilization by filtrat ion, was 9.0 mo l/mol ± 0.0\
(mean of 16 preparat ions). Fo r tile con trol experi ments. a 1.0 g samp le of albumin was
carr ied through the procedure in the abs ence of oleic acid.
2,2,5 I'~q-Oleic llCid preparation and administration.
Rudiofuhcllcd tracer [14C].0Icic acid was added at 0.5 ).l.Ci/m L medium.
xnhscqucnuv. Iriacylgy lcerol and cholestcryl ester were separated by silica ge l TLC and
the appro pria te regions of silica were sc raped into vials co ntaining scintillation cocktail
(Scin tiv crsc I from Fisher). Act ivity was measured in a scintilla tion counter (1214
Rackbcra LSC from LKB WALL AC).
2.2.6 Lipid ex traction and thin layer ch romatography.
After incubation . cells were washed twice with ice-cold PBS and the cell pellet
was tr eated for 60 min with 2 mL 2:1 (v/ v) chloroform/methan ol tw ice and the extracts
were pooled. The residual insolu ble materi al was dissolve d in I m ", 0.1 M NaOH for
prote in measure ment by the Lowr y's met hod (Lowry et a l., 195 1). The lipi d extracts
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were evaporated unde r a stream of nitrogen und reui);Sllln~d in 1tltl ILL
chlorotorm/methanol. 50 p L aliquo ts of extract we re applied to silica gel T IT plates al\\l
the lipids were separa ted by development with 75::!5:1 hcxuuc/dictbv l ether/ace tic acid.
Aliq ucts o f the medium were also ext racted with J volumes Il l' cblorofonwmcthauol :!:1
(v/,,) for 60 min twice. The organic phase \\':ls washed twice with I 1111
chloroform/met hanol 2:1 (v/v) and I m l 0.05% KOll to remov e the rcnmining radioac tive
free oleate . The samp le was then processed in same way ' IS the cell extrac ts to measure
mediu m triglyceride . cholestero l. and cholesterol ester.
2.2.7 Measurement of cho lestero l and ch oles tcryl es ter hy I.: :l .~
chroma togra phy/ mass spectrometry
Measuremen t of free and es te rified cholestero l was accomplished hy gas
chromatography/mass spectrometry (GOMS) using a modification of the metho d of
Lin net (199 4). In outlin e. the method involves extracting the cholesterol and cho les terol
ester spots from silica gel TLC plates with 2:1 chlorofor m/ methan ol. 'lddi ng nl mL N-
mc thyl-N-trimethylsi lylfl uoroace tamide and lncubuting for 30 mill at 511°C tn produce
vola tile derivat ives. For the measu rement of cholestero l ester. the este r traction elu ted
from the TLC was hyd rolyzed with ethano l and KOH for 3 hours at 37°C (Linn et. 1(1)4)
prior to derivitization. The derivatizcd extracts were injected into a I lcwlctt-I'ackard (jC
5890 Gas Chromatography coup led to a Hewlett-Packard MS 5970 Mass Selective
Detector at a port tempera ture of 240°C. The resulting mass spect ra we re compared
l8
au tomatica lly with the cholesterol specuum from the machine's stored library o f mass
spectra. T ropic acid was used as an internal standard.
2,2.8 Determinal ion of Cholestero l and Cho lcsteryl Esle r ~'ith D-
l'hthal:.Jldehyde.
An~r silica gel TLC.l ipids were visualized temporarily with iodine vapour and the
(ructions corresponding to cholesterol and cho lesterol ester were scrape d into glass.
stoppered tubes and extracted with Sml chloroform. The tubes were then centri fuged for
S min at 1000 g. Aliquots (1 mL) of the chloroform layer were pipetted in duplicate into
co lorimeter tubes and the solvent was evapo rated under nitrogen . Then 2 mL 0 -
phrhalaldehyde reagent (prepared 115 in Rudel and Morris. 1913) was added to each tube
with thorou gh mixing to ensure comp lete solution of the lipids. The solution was stood
lor approximately 10min later. Then I mL su lphuric acid was added with care and the
absorbance read at 550 nm within 10 to 90 min.
2.2 .9 Sulforhotla mine 8 (S RB) auay
The SRB assay provides a se nsitive method for estimating cell viability in
cytotoxicity studies. It is cla imed (Rubinstein et el.• 1990) to offer several advantages
over the temzclium bromide (MIT) assay (Kubo ta et al., 1993) for very large sca le drug
screening. The SRB assay provides a better linearity with cell numb er, a higher
sensitivity. and its staining properties are not cell-line dependen t (Keepe r et al., 1991:
2.
Kuba la et al., 1993). The optical densities of SRD can be measured over II b road range
of visible wave lengths in either spcctrophoromctcrs or well plate renders.
This procedure is essemlally that ofSkehan ct al.( 11)')0) with minor ruod ulc.ulo ns.
The cells were washed with CMF·PBS twice and then fixed in situ by addition uf ':;o p i
of co ld 50% (wt/vol) trichloroacetic acid (linal concentration. 10%) . Ane r lnculuning
for 60 minutes at 4°C. the supernatant was discarded and theplates washed live times
with tap water and dr ied. One hundred microliters or SRB solution (tl .4% wt/vol in I'Yn
acetic acid) were added to each well and the culture W,lS kept for 30 minutes at ro om
temperature (Hall et al., 1(9 3). The unbound SRB was re moved by washing five times
with 1% acetic acid. Then the plates were uir dried. The bound stilin was solubilized
with unbuffered 10 mM Tria and the optical density read on an uutonuucd
spec trophotometric plate reader at 540 run.
2.2.10 Enzymatic Investi gat ions on Cell Membrane Permcahillty
The basis of this approach is tha t damaged cell plasma membranes lea k cytosolic
enzymes into their surrounding extracellular environment. The presen ce of these enzyme s
can be used as a quali tative and quanti tative index of cell damage.
After cells were incubated for various periods of time with the experim ental
reage nts, the culture medium was analyzed for lactate dehydrogenase (LD I-I). alanine
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amino transferase (ALT) and aspartate amin otransfe rase (AST). Leve ls of these three
enzym es arc ro utinely used in cli nical ch e mistry as indices of liver damage. The LD H
leaka g e to the e xuaccf luhi r medium was used as a cytotoxicity ind e x for He pG2 cells
in cu lture by Neuman e t al. ( 199 3).
Allmeasureme nts were made using Kodak Ektachem Clinical Chemistry slides o n
a Kod ak Ektac hcm700 Analyzer . The Ko d ak Ektachem Clinical Chemist ry Sl ide syste m
consis ts of 11 dry. mu ltilayered . self-con tained anal ytical element coated o n a clear
polyes ter support. An 11 J.lL d rop of sample is deposited on the slide an d even ly
distrib uted throu gh the spreading layer wh ich also contains the appropriate subs trates for
the enzyme be ing assayed. Enzy mes arc assayed by following thechange in absorbance
at )4U nm and 37°C as NADH is oxidised to NAO · .
Lqt'lqre dehydrogl!Ua.~e
Th e assay for lacta te dehyd rogenase (LDH) uses pyruvate and NADH as
substrate s to generate lact at e and NAD ' ,
l DH
Pyruvat e + NAO l-1+ W --- ••.•••--- -- ..•> L actate + NAD+
"'''mi/le aminlJ/ranskras£
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Alanine nminorransfcruse catalyzes tile transfer of the amino l;rllUPof L·
alanine to c -kercgtutararc to produce pyruvate and glu tamate. ]lyridox'll·5·
phos phate(PyP l is a cofactor. Lactate d ehydrogenase (LDll) then catalyzes t l ~
conversion of pyruvate and NADll to lactate and NAD'.
ALT
Alan ine + a-Ketoglutarate •••••••-•..•> Pyruvate + Glutamate
PyP
LDH
Pyruvate + NADH+ H' •••-----•••••••> Lactate + NAD'
~l.l'Qqrlatr! Aminmrt/n.\·fi!ra .\·c
Aspart ate aminotransferase catalyzes the transfer of thc amino gmup of L.
aspartate to cc-ketoghnarate, using pyrldoxal-d-phosphatc (PyP) as a cofactor, tu
prod uce glutamate and oxatoacetatc. Oxcloaccratc and NADII arc converted ro
malate and NAO' by malate dehydrogenase,
AST
Aspartate + u-Kcteglutarate --•••••••••--- ••..•> Oxnloacctatc + Glutamate
PyP
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MDH
Oxaloecc tatc + NADH + W ~~•..•.••••••••.•••••••> Malate + NAO'
2.2.11 Quantllatlon of cell cycle composition by flow eytomct ry
Flow cyromctry was conducted only on HepG2 cell cultures grow-n for 24 a nd 48
hours with oleic acid/BSA complex alone (0.8 mM), lovastatin alone (10, 50 a nd 100
j.tM), or o leic acid\BSA and lovastatin. The procedure was performed as described
previously with slight modification (McClosky ct al.. I 994). The basis of' the met hod is
thai DNA is com plexed with ethidium catio ns and the DNA concentration o f each
individual cell is measured fluorornetricallyas it passes across a detector: relative DNA
concentrat ion permits determination of the posit ionof each cell in the cell cycle.
To prepare cells for flow cytometric analysis, 2 X 106 cells were harveste d and
fixed in 95% ethanol for 20 minutes at 4°C. Th e fixed cells were washed with PBS and
resuspended in 250 ul, of RNase solution ( 100 IlglmL) and incubated at 37"C fo r 30
minutes. After washing the cells wit h buffer to remove RNase, 250 JlL of prop idium
iodi de solution (50J-lgfmL PI in 0.6% Triton (TX ·IOOin PBS» was added, mixed gently,
and held at 4°Cove rnightin thedark. Nextday , thevo lume was increased to I mL with
PBS. Propidium Fluorescence of each cell in the specimen was measured on a Becton
Dickinson Immunoc ytometry System (FACStar Plus). Data on relative membersh ip at
di fferent stages in the cell cycle and the presence of a svb-Gn(hypodiploid or Ml) peak
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wereco llected. stored an d analyzed with Becton Dic kinson LYSYS 11software.
2,2.12 l\<t orphol o gical Amd}'sis usin g Elcctmn Mic rnsclIPY
Cells \Vere washed with PBS and fixed overnig ht at O·C in mixtu re Ill' 40/0
paraformaldehyde.Sw g lutaraldehydeand0. 1Msodium cacod ylatebuffer (pi[ 7 A ). Afte r
fixation. cells were scraped outand washed threetim es for 5 mlncach in aO.2 M sodium
cacody latebuffer. thece lls were post-fixed in 1% osmiurntct rcxtdc in cacodyla te huffcr ,
dehydra ted thro ugh a gradedse ries of alcohols and embedded in TAAIJ epo xy resin .
Ultrath in sections were cut on a REICHERY OMUJ ultra tomc and examined with .1
JOEL. 1200 EX, electron microscope. Thi s proced ure is based essentially on published
methods (Bouma et al., 1989; Pullinger er al.. 1989) .
2.2.13 Ap olipoprotcin QUllnfitation
ApoproteinsA an d B levels inculture mediawe remeasuredusingsped fie clinica l
lmmunochcmic ul assayreagents fromOrion Dingnostica. The principle ofthe method is
that excess specific antibody is permiUed to combine with th e untigcn under conditions
where precipita tion does not lake place. Th e turbidit y of the specime n is propo rtional to
theam o unt of an tigen presentand wasmea suredon a Monourch Autounalyscr at )40 nm.
2.2.14 S ta tistical Analys is
Each cytotoxic determination was done in 6 wells per concentration in 12
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experim ents and the mea n value was expre ssed us a peJCCnta ge :t SO of the re spective
controls. Metabolic assays were carried out witha t least 6 valuesas will be m entioned
untk."l' T able 3.5 . The d ose-respon se curve represents perc enlage value ± S O of the
rcspectivceont ro ls. Slal is tic.1lsignificance was calcu lated by the Studenr's t-test , Analysis
of Variance and Multiple Comparison by Sc hcffe's test using Sfalistica l Analysis System
fSAS) S oftware Vers ion 6 .09.
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CHAPTER 3
RESULTS
36
In this investigation, the cytotoxicity effects of acute and chronic exposure of
lovusuuin on HcpG2 celts were studied. A comparison was also made between the effect
of treatment with lo vastatin alone or supplemented with 0.11mM oleic acid in complex
with bovine serum albumin. The rationale for the addition of oleic acidlBSA was to
determine if suppleme ntation with an external source of fatty acid to promote intrace llular
synthesis of triacylglyccrols and cholesteryl ester would have an effect on the response
to lovastaun.
Lovastatin toxicity was investigated by the following independent methods:
Direct Sulforhodamine B staining for cell viability .
Detection of the intracellular leakage of enzymes lactate dehydrogenase
(LDH), aspartate aminotransferase (ASn end alanine aminotransferase
(ALT) into the culture medium as an indicator of plasma membrane
disrupt ion.
Visua lization of morphological changes by transmission electron
microscopy.
Cell cy cle analysis and detection of apoptosis by flow cytometry.
Detection of the effects on lipid metabolism
3. t Resu lts or S utphor hoda mine B (SRB) Analyses or Cell Viability.
For 24·hour acute exp osure. the effects of lovas tatin co ncentration on HepG2
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cytoviability are shown in (Figures 3.[ and 3.2). AI tovasmrin conccntrnrions of 10 ItM
and below no significant reduction incytoviability'vas observed. At 50 11 Mand IUO fiM.
cell viability was reduced to 79.3% and 61.9%. respectively ({I = It 05).
In the case of chron icexposure (2. 3. 4, 6 and 8 days) the effects oflow lovasnuin
concentrations (2.5 flM and below) were essentially the same as for ~4-h tlur chronic
exposure as shown in (Figure3.1. A-E). Marginally significant change Irnmcontrol with
5 and 10 flM started to show from 2-8 days (a=O.05). However at high concentrations
(50 and 100 pM) cell dea th was much greater, Af'tcr 8 days ofex posure to 50 and 100
11M lovastatin, cell viabilities had been reduced 10 15.2% and 0.73%. respectively (It.=
0.05. P -c0.000I) . As s hown in Figure 3.3. supplementation of the lovasnnin treatments
with 0.8 IlMoleic aeidIBSA had a dramaticeffecton cell viab ility. A lthough lovastatin
concentrations of 10 j.1Mand below had no significanteffect on cell viabilities. cell death
was evide nt at these low concentra tionswhen oleic acid was also pre sent in the culture
media (<<=0.05 , p < 0.0025). For comparison. cell viabilities after 24-hour acute
exposure 10 10, 50 and 100 j.lM lovasnnin and 0.8 I-tM oleic acid were RI.J%. 55% and
45%, respectively. In the caseof lovastatin alone. the comparable viabilitieswere 9J.5%.
79.3% and 61.9%, respectively.
3,2 Results of Enzyme Leakag e Studies
Figures 3.4. and 3.5 . demonstratethe effect o f increasing lcvnstatinconcentration
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Fig. 3.1. Acute and chronic cytotoxicity effects of lovastatin
on HepG2 cells using SRB assa y.
HcpG2cdls were incubated for24 boon to 3 days in lin:pre senceor absenceof lovssl8tin.
Cytotoxicity WlUeseesed by lhesulforllodamine 8 (SRB) a.my u described in themethod
section Doto arc cxpn:ssed asP=flllgl:' of SRB incontrol cells. Eacll point reprcSl.'lI13
the meNl(± SD)of6rcplicalcw ellspcrpoint in 12 C);perime!l13. (or:: =0.05). The optk:al
demilicsincontrol cullUre3 were1.636 :to.33 for 24hours, 1.753:1: 0.324 for 2 days,1.596
:to.:nfor 3 da y:l. t S53 ± 0.31 for 6 days llld 1.490 Z 0 .S6 for IIIby"
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Fig. 3.2. Inclusive representation of Fig. 3.1, Acute and chronic
cytotoxicity effects of lovastatin on HepG2 cells using
SRBassay .
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Fig. 3.3. Acute cytotoxicity effects of lovastatin with and without
0.8 mM oleic acid IBSA for 2.. hours usingSRB assay.
HepG2 cells were cultured for24 hours in the presence or absence oCO.8mM oleic
acidIBSAwithor without lovastatin. Cytotoxicitywas assessed by Ihe
sulforhodamine B (SRB)assay. Data areexpressedas percentage oCSRBcontrol
cells. The graph shows the means (± SO) or6 replicate wells per point in 12
experiments. The optical densitiesin controlcultures were 1.636± 0.33 for24
hourswithout anytreatmentand J.538 ± 0,28 for 24hourswith0.8 mM oleicacid!
BSA. [ec=0 .05).
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Fig. 3.4. Acute and chrome cytotoxicity effects of lovastatm on
HepG2 cells using LDH leakage into the extracellular
mediwn.
HepG2cellswefCincuhl!ed for 24 hOlU:J 108 d4ya in the presence or absence oflo vaslBlin.
Cytotoxicitywu lISSC:SSed by l..:tate dehydrogenase (Lmo lcabS" iruothe I:XlJloCCllular
mc:diwn. Data are expressed IS percentagesof LDH i>l;livity in control cx:1I5. E"'~ point
representsthe1TIl:1IlIS (± SO) of6 replicate wen, per pointin 12 experiments. (<<" 0.05). The
basal l1lles(UlL)in ccnucl cuhureewere Ig2.S± 6.2 for 24 houra, 181.6 % 10.7 for2 day,,_
178.5 ± 10.56 fOf3 dIIys, 185.5 <!: 9.35 for 6 daysand 1'JO.9 <!:9.87 for8 do.y~
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Fig. 3.5. Inclusive representation of Fig. 3.4, Acute and chronic
cytotoxicity effects of Iovastatin on HepG2 cells using LDH
leakage into the extracellular medium.
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on the activity of LDH in the cultu re medium. These results dcmo nsrrmc th" t I.DII
leakage and SRB staining arc comparab le. The correlat ion coefficients belween I.D II and
SRB for 24 hours. 3 d"ys and 6 days o r exposure arc tJ.IJX1. tl .IJX6 and n.!)'):!,
respect ivel y. LDH was more sensi tive lo r detect ing dar nngc nt :' ~tM after 24 hours
(u ""O.05 . P <0 .00 1). Lovastatin with 0.8 mM oleic acidlBSA mlded, LDII leakage
analysis wns also able to demons trate morc pronounced da mage and a lower action
thresho ld (Figure 3.6).
When cell damage was assessed by ana lysis of AST and ALI' Icuk ugc (Figurcs 3.7
· 3. 10), it was found that a 10 J.1M tovastetin concentration wes sufficicnt to eli cit enzyme
leakage above control values ancr a 24- hour exposure (Figures J .X & 3. 10). With cells
exposed to 10 IlM lovastatin for 3 days, significant AST and ALT lcukugc va lues of 19.11
± 1.7 (p <0.0025) and 6 ± 1,4 (p <0.0001) UlL were noted in comparison In contro l
value s of 14.6±0.5 and 1.0 UlL. respec tively. An increase in ALT with 5 JIM was
detect ed aft er 3 days (16.9 ±0.8 UlL) ((1""0.05 , p <0.005). By 8 days eve n the contro l
cultures were leaking sign ificant amounts of AST end ALT (F igure J. 7. E and 3.9 .E). In
essence, the AST and ALT measur ements gave results similar 10 those of LOl l and SRB,
except that the AST and ALI were mo re sensiti ve in detecting damage uncr longe r
incubation time specially ALI after 8 days it recorded leakage for even control and 5 11M
afte r 3 da ys (0.0025). But LDH is more sens itive at lower lovusuuin conccn trations.G
uM after 24 ho urs). especiall y dur ing the first three days (u =O.05 • 1'<0.(01).
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Fig. 3.6. Acute cytotoxicity effects of lovostatin with and without
0.8 mM oleic acid IBSA for 24 hours usingLDHassay.
HepG2 cells were cultured for 24 hours in the presence or absence oCO.8mM oleic
acidIBSAwith or without lovastatin. Cytotoxicitywasassessed bythe lactate
dehydrogenase (LOR) leakage to the extracellular medium. Data are expressed as
percentage ofLDH activity in untreated lovastatin cells. The graph showsthe means
(:I:SO) of6 replicate wells per point in 12 experiments. The basal rate in control
cultures were 182.5:6.2 for 24 hours without any treatment and 181.8 :l:: 14.74 UIL
for 24 hours with 0.8 mM oleic acidIBSA. (cc=0.05).
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Fig. 3.7. Acute and chronic cytotoxicityeffects of lovastatin on
HepG2 cells using AST leakage into the extracellular
medium.
HepG2 cells were incubeted for 24 holltSto 8 days in thc pre!Cllceor ab:lCllCCof lovuta tin.
Cytotoxicity wu assessedby ASTleakage intothe extracellular medium. Oala arc expressed
"" VII- ElICh point reprC$oefll'l the meww (,t 50) 0(6 replicate welts per point in 12
expcrimenls. (oc:oo.oS).
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Fig. 3.8. Inclusive representation of Fig. 3.7, Acute and chronic
cytotoxicity effects of lovastatin on HepG2 cells us ing AST
leakage into the extracellular medium.
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Fig. 3.9. Acute and chronic cytotoxicity effects of lovastatin on
HepG2 cells usingALT leakage into the extracellular
medium.
HepG2cells wereincubated for24 hoursto 8 da)'ll in the presence Of .b3CrICC of IovBSlatin
CytotoxicityW~ use!SCld by ALT leakage intothe c)(\[acellu[ar medium. 0 .11 are expre!l.'lOd
ISUIL. Each pointrepresents the means(* SO) of 6 rcpticete .....ells per point in 12
experiments. (<:c -O .OS).
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Fig. 3.10. Inclusive representation of Fig. 3.9, Acute and chronic
cytotoxicity effectsof lovastatin on HepG2cells using
ALT leakageinto the extracellular medium.
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When 0.8 J.lMoleic ncidlBSA was added for 24 hours. significant AST and ALT
leakage was noted; even in the contro l cultures (Figures 3.11 and 3.12). ClcarlY. lhl:
damage induced by lovastarinat [ow lcvastatinconcentrations in the presenceuf oleicadd
was due \0 thc nutritional supplement and its interaction with lovastntin (ll ""IU15).
ONBSA enhanced the lcvestatin toxic effect.
The cytotoxici ty of ole ic acid is apparent and it is diffic ult to consider this
compound as simply a non-toxic nutritional supplement specially in long-term tovnsuuin
studies. The re is 0. clear synergistic effect and lovastatin and oleic acid produced grouter
AST and ALT leakage than lovastaun alone.
3.3 Results of Tra nsmission Eleelron Microscopy
l lte morphological effects of lovastaun exposure on HcpG2 cells were assessed
by transmission electron microscopy. Representative ultrustructuml features arc shown
in Figures 3.13-25.
Exposure of HepG2 cells to various concentrations of lovustatin produced
detectable morp hological changes. Several features were identified and were combined
to generate a 3-point scale of damage. mild{+), moderate (++) and severe (+++) Crable
3.1). It was also noted whether the stated features were seen in the majority (A) or
minority (8 ) of cells examined (Tables 3.2-0 & b). Cells were considered as
50
-+-lD.!N:tin
-a- Iw.+OAl BSA
±4.8
± 1.640
:::r2. 30 ±2.1 ± 1.6 ± 1.8 ± IA
~<2)~.8
10 ±O.I ±2.3 ± lA ±1.5 ±1.6 ±2A
10 00 100
o+----.--...---,---,---,---,----,
o 0.25 0.5 2.5 5
[LovastatinlllM
Fig.3.11. Acute cytotoxicity effectsof lovastatin withand without
0.8 mMoleicacid IBSA for 24 hoursusingALT leakage
into extracellular medium.
DataareexpressedasUIL. Thegraphshowsthemeans(± SO)of6 replicatewells
perpoint in 12experiments. (ex: =0 .05).
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Fig. 3.12. Acute cytotoxicity effects of lovastatin with and without
0.8 mM oleic acid IBSAfor 24 hoursusing ASTleakage
into extracellular medium.
Dataare expressedasUIL. Thegraphshowsthe means (±SD) of6 replicate wells
per point in 12experiments. (IX= 0.05).
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Fig.J.D. Electron micrograph showing an essential ly normal cell (contro l cells
after 24 hours) . (Original magnification x 1O,400).
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Fig.3.14. Electron micrograph showing generalized cellular swelling and loss of
microvilli. Mitochondrial abnormalities are also noted (M), including
swelling and cristae reduction (2.5 J.lM lovastatin after 3 days). (Original
magnification x 10,400).
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Fig.3.t5 . Electron micrograph showing early ribosomal separation and dispersion
(arrows). Mitochondrial swelling and cristae reduction are also evident
(M) (5 IlM lovastatin and 0.8 roM OAIBSA after 24 hours). (Original
magnification x 10,400) .
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Fig.J .16. Electron micrograph showing mitochondrial abnormalities (M) in the form
of swelling, vacuoles and large granules. The cell membrane is also
disrupted (arrows) (10 J.LM lovastatin and 0.8 roM ONBSA after 24
hours). (Original magnification x 15,600).
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\Fig.3.17. Electron micrograph showing nuclear indentation (N), cytoplasmic lipid
(L) droplets and blebbing (arrows) (50 J.lM lovastatin after 3 days.
(Original magnification x 7,800).
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Fig.3.18. Electron micrograph showing nuclear densities and early chromatin
condensation (arrow). Abnormal mitochondria are also seen (10 I-lM
lovastatin and 0.8 ruM: OAIBSA afte r 24 hours. (Original magnification
x 11,500 ).
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Fig.3.19. Electron microgra ph showing ribosomal separation and dispersion along
with ear ly endoplasmic reticulum swelling. A myelin figure (arrow)
and lipid droplets (L) cytoplasmic lipid drop lets are also noted (100 IlM
lovastatin after 3 days) . (Original magnificatio n x 16,800).
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Fig.3.20. Electron micrograph showing cells with nuclear densities (arrow) and
chromatin condensation. Cytoplasmic vacuoles are also evident (V) (50
J.1M afte r 6 days. (Original magnification x 8,400) .
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Fig .3.21. Electron micrograph show-ing early loss of structural details. Preserved
organelles exhibit mitochondrial disruption (arrow heads) and a small
myelin figure (arrow). The nucleus features chromatin condensation (100
J.1M after 2 days. (Original magnification x 12,600).
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Fig.3.22. Electron micrograph showing myelin figures (arrows) and nuclear
densities (arrow heads) (50 IlM lovastatin after 6 days). (Original
magn ificatio n x 15,600) .
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Fig.3.23. Electron micrograph of shrunken cell s showing cell membrane disruption
and endoplasmic reticulum dilation (arrow). Mitochondrial number is
increased (M) ( 100 J.1M lovastatin after 24 hours). (Original
magnification )( 5.700).
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Fig.3.24. Electron micrograph of apoptotic bodies showing condensed nuclear
chromatin (50 IlM lovastatin and 0.8 m..\1 OAIBSAC after 24 hours).
(Original magnification )( 14.000).
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Fig.3.25 . Electron micrograph showing a necrotic cell with loss of cytoplasmic
and nuclear integrity (100 )..lM lovastatin after 3 days). (Original
magnification x 12,600 ).
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Table 3.1 GRADES OF MORP HOLOGIC CHANGES DETECTED
BY ELECT RON MICROSCOPY.
FEATURES
~ lildl+l ,Cl:lIular swelling 1genemliml l (Figs. 3.13.'/.;3.1-1\
.Mito~hoodri~1 swelling (Fig. 3.1~1
·.\ liloehondri~1 v~euDles ( gr~ nu lc5 ) IFig. 3.16\
-Mitcchcndnal ~risl~e recccuo n (Figs. 3. t~ ."<: 3.18\
.{.'>· topt~smie vacuolizalion lF ig. 3.201
.Lo~s of microvilli (Fig. J .I ~)
-Ribosemal dispet1ion(Fig. J. 15)
·Blebbing (Figure J .l7I
-Myetln Figures (Fig. 3.1'l)
-Ltpid droplclsIFigs.J.I7&J.191
-Condensationofnude~r chrerrsninIFit:. 3.18\
-ceushrinking (Figs. 3.20 & 3.22)
.Nuc lcnr densit ies (Figs. l .IS & 3.20)
Severe!++"') .Oisruption of cl:l1tnembrane (Fit:s. l ,22 &:3.24)
-Mitoc hondrlal dislUplion (Fig. 3.21)
.E~treme chromatin d umping (Fig. 3.21)
·Apo ploliebo d ics (Fig.3 .24)
·Lossofs lnx:lurnlde lails(Fig.3.2I)
·Necro sisI Fig.3.25)
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morpholo~ically damaged if one or more of the following feat ures were noted :
Cell mem brane fragmentation .
Mitochondr ia deran gement (disappearance of the cristae. increased size).
Myelin Eig ures.
CclluJ:n swelling.
CytO(llasmic eccumulaion of globules.
Presence o f blcbb ing.
Celldeath Wl\5 ind icated by the prese nceof one or mor e of the following features:
Chromatin condensation.
Lossor int racellular structural details .
Ccmplere disruptio n of the cell membrane.
ApoplOlic bodies
3J.1 F.rrtcls of IOVlst31in alone
The morp hologic a l changes produced by exposure 10 lovas enn a lone are
summarized in Table 3.2.n. These data incl ude lovastctin concentrations from 2.5 10100
~lM and exposure times from I 10 6 days. Concentrat ions less than2.5 f.IM did nOIshow
significant change s as compared 10 control.
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Grades of morphologic changes in Ik pG 2 cells exposed III
lovastatin nlonc.
Incubation Lcvasanu conccurrunon (fLI\tI)
time (days)
2.5 5 10 50 Ion
I ~ + t B) H '+{A)
2 +(13) H (B} I-++ {A)
3 +(8) +( B) ++(B) ++tA) +++ (1\)
6 +(8 ) ++(A) ++ (A) +++( A ) +++t i\l
T ABL E 3.2-b Grades of morp hologic changes in IkpG::! cells cspllscd III
lovastatin supplemented with a.H 111M OA /m;/\ uf'tcr one day
incubation.
Lovastatin concentration (p M)
+ O.8mMONI3SA
otV BSA- 1 2.5 5 10
+(8 ) I +(B) I++ ( A ) I++ IA) 50 rnoI+++(A ) I I--H (AJ
(A) Morphologic changes seen in the majority of cells.
(B) Morphologic changes seen in the minority of cells.
Cells incubated for 4H hours with 2.5 - 5 llM lcvastatin exhibi ted no obvious
degenerative changes. Formation of intranuclear dense regions . cellular swelling, and
formation of lipid-vacuoles was observed after incubation for 3 days for 2.5 ~ lM. With
5 ~lM, mitochondrial enlargement and cristae destruction were observed after 3 days. This
is classi fied as ' mild' structural damage. Aller 6 days, mitochondrial changes and
vacuoles (mild chcndc} appeared in 2.5 ~tM , whereas red uction in mitocho ndrial cristae
and microvilli (moderate change) was shown with 5 pM lovastatin concentra tion.
Cells incubated with 10 ~tM lovasmtin developed ' mild' structural damage by day
~ . Lipid-filled vacuoles appeared and mitochondrial cristae disappeared by day 3, The
cells appeared somewhat shrunken as compared with the controls butthe growth rate and
generalmorphology were essentially normal. By day 6, some cells began to demonstrate
shrinkage, chromatincondensation around the nuclear membrane. cytoplasmic vacuolation.
mitochondrial swelling with cristae reduction. cytoplasmic enlargement. and almost
comple te disappearance of microvilli. However. some cells preserved normal nuclei.
When cells were incubated for 24 hours with tovasraun in the absence of oleic
add. morphological changes were only observed at high lovastarin concen trations (50 and
100 ~IM) . With :!4-hour exposure of 50 ~IM lovastntin changes were classified as
'mode rate ' There was an Increase in the number of mitochondria but the mitochondria
exhibited swelling. cristae reduction. and large lipid vacuoles. There was also ribosomal
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separation. mild chromatin condensation with nppcamucc of dense regions within the
nuclei. There were ear ly indicmiolls of upoptosis. Thc nuclear dcnshi..-s were a lmuSl
twice the size of those observed in cont rol cells. Aller 4Nhours aptlptntlc cells were
evide nt. By day 6 structural damage was 'severe' : myelin figures. hlcbbing , and nuclear
indentation were evident in the majority of cells. Apoptotic hcnli..,s appeared. ~tallY cells
were dead but a few uppurcmly normal cells remained. The general imprcsxion is tluua
6-day incubation with 50 11M lovastatin was comparable in morphological changes ttl 24-
48 hours expos ure 10 100 f-l M lovasmtin.
Severe changes were noted wsh 100 ~lM lovastaun lor 24-htlur expos ure.
Result ing structural damage was regarded as 'sev ere' Mitochondria hud increased in
number but their cristae almost disappeared and vacuoles had appeared. An increased
number of mitochondria could be attributed to the appearance or aggregated mitochondria.
Cytoplasmic lipid droplets nppcnred. Blebbing was a characteristic feature and some of
the cel ls were undergoing upoptosls. T he cell nuclei were variable in size; some were as
large as those of normal cells but others were more compact ami densely staining.
Some cells were noted 10 have developed udditionul. progressive morpholog ical
changes: the nuclei o f these cells were fragmented into 11 cluster nf vesicles: and the
massive cytoplasm-tille d blebs began to pinch-o il and detach (Figure 3.2(1). l.oss nf
cytoplasm by bleb detachment may partly explain the observed cytopfusmlc shrinkage.
70
Fig.3.26 . Electron micrograph showing cytoplasm- filled bleb s beginning to pinch-
off and detach (arrow) (100 ~M lovastatin after 24 hours) (Original
magnificat ion )( 9.000).
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Fig.3.27. Electron micrograph showing apoptotic body with mixed features (100
~M lovastatin after 3 days). (Original magnification x 12.600) .
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The final state in this degenerative apoptotic process is shown in Figures ],2 4 and ],27 ,
By 48 hours necrotic cells and a few apoptotie bodies were observed. Alter 72 hours
lipid dropl et s were huge lind the mitochondria though still high in number were swollen
and cristae had completely disappeared. Cytop lasmic membranes were disintegrati ng.
Upon further incubation with 100 11M lovastenn for 2-6 days it was observed that
some of the cells. although damaged. were not progressing to cell death (typical apoptotic
bodies. seconda ry necrosis .and necrosis) as qu ick ly us the others. As will be discussed
under flow cytometry. the reason for this phenomenon might have been thai lovastatin-
induced cell death does not take place at all stages in the cell cycle. Cells in S phase
(inte rphase) arc resistant. Death takes place during the transition to G21M (ind uction of
mitosis). In ral liver induction of both apoprosis and necros is has been desc ribed for
hepatotoxic agents in I'im (Ledda-Cclu mbano et 'II.. 1991) and T call ill vitro (Aten et al..
19( 5),
3,3.2 Effects of lovastat in and oleic acid
The structural consequences of supplement ing cultures with 0.8 roM oleic
acid/BSA were dramatic. even after 24 hours (Table ] .2.b). Cells cultu red wi th oleic
ilci J IBSA without lovastatin exhibited 'm ild ' structural damage (Table 3. 1), This became
' moderate' at Iovustatin concentratic ns between 5 11M and 10 11M lovastarin and 'sev ere'
with 50 11Mlovustatin.
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Characteristic damage a fter :!-I·hour exposure to o leic aci,JfBSA alone included
changes to the mitochondria (increased in number with reduction in number of cristae.
appearance of intrar nitochcndrial vacuoles ilnd grcnulcu). cytosolic liphl droplets. and
swelling of the endoplasmic reticulum. Addition of lovustatin lip to a conccm rauon Il l'
5~IM did not significantly increase the structural damage lifter 24 hours incubation.
When the cells were incuba ted with 10 ~lM lovusunin and 0.1\mM oleic aciJi BSA
for 24 hor rs. the number and the size of lipid droplets W:L'i Increased furtller.
mitocho ndrial cristae disappeared. and chromatin started 10 clump. Some of the cells
showed necrotic features. Cell damage with SO~IM lovnstntin and oleic m:iJIBSi\ was
more severe than at 10 ~IM. Myelin figures and cell hlebbing was evident. Some Ill' the
cells showed advanced apoptosis. With I00 ~IM lovastaun and oleic acidlRSA. cells
exhibited rounding-up or shrinkage and non-refringent cells Flouting in the medium (i.c
no longer attached to the culture dish surface monolayer ) were observed. The remaining
adherent monolayer cells exhibited mitochondrial changes. huge lipid droplets. d isruption
uf ribosomes, and apoptotic bodies. A level of damage wns achieved in 24 hours with
100 11Mlovastarin and 0.8 mM oleic ncidiBSA comparable to that of IDO flM lovasumn
alone in 3-4 days.
Trans mission electron microscopy of' the floating cells recovered from the medium
demonstrated typical apoptotic bodies with clear features of' secondary necrosis {i.e mixed
featu res of apoptcsis (Figure 3.27) and necrosis (Figure 3.25). That these cells were in
fact dead was verified independently by SRB assay.
JA Results IIf Flow Cytometry
In order to assess the extent of lovestatin-induced apoptosis and to observe whether
this process was selective to any phase of the cell cycle. I studied the cell cycle
distribution of IlcpG2 cells treated with 10. 50. and 100 11M lovastatm with and without
U.S 111M ON OSA and untreated control (Tables 3.3 end 3.4, Figures 3.28 and 3.29).
Flow cytomeiric analysis of propidium iodide-stained nuclei was performed for 24 and
48 hours (average of three experiments). The appearance of cells with a DNA content
less than G I, characteristic of early apoptotic cells (sub-Gt MI), could be observed utter
the addition of 100 ~IM Iovesrattn lor24 hours (Figure 3.28 D). Cell arrest in GI mixed
with 25.3 % apoplotie cells was seen with 50 ~IM after 48 hour with lovastarin alone
(Figure J .28 G). In case ofONBSA. the M l region appeared with 50 11M after 24 hour
and with 100 ~IM lovastatin after 48 hour (Figure 3.29 C & H).
3....1 Effects of lovnstatin alone
Cells with 10 ~IM lovasrctin after 48 hours sho-vedarrest in the 0 1 phase with a
decrease in the S phase and a pronounced G2IM arrest. Treatment with 10 11M produced
IlO sigmficnru change during the first 24 hours. Although there was no obvious change
in the totnl number of S phase cells after 24 hours, there was a decrease in the number
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TABLE 3.3 Effect of Lovastatin on Ikp02 Cell Cycle phase distribution
after 24 and 48 hours incubation' .
Tr~almenl lime GI S G~iM "I'"plolic .
I~~ll Ih,) ~c ll~ \~t l · .l
0
"
7J.8 ±OA SAtl.O ~O..lt IA CI.~HO,.1
10
"
76.0±O.7 6.6iO ,6 l' l,HO .a \.<)lUll.::!
50
"
76,OtO,6 'I.O±O..l 1 ~±O , 7 ILSIHI.J
100
"
6 1 .3±0, ~ I).S:tO.S 2'),~±0 .~ 5l. It O.'1
0 4S 7J .St.O.7 S.6tO.3 20.'H O.S n,SiO .7
10 4S nOtO.5 3.3:t0.4 1.1.7iS.O 4'I.O±O.4
50 4S SO.7iO.S 8.'HO.6 lO.4tO.a n .3l0 ,<j
100 4S 41,9tO.6 34.4tO '(, ~.1 . 7i0 .9 1t,711. t
TABLE 3.4 Effect of Lovastatin supplemented with 0.8 mM OAIBSA on
HcpG2 Cell Cycle phase distribution after 24 urul 48 hours
incubation' ,
Trealm ent time GI S U2IM 1\1l<1~I(lt ic ccll~
111 ~·n (hr) (MI %)
0
"
71.810.4 4.5:t1.t 24.St.O.2 2..ltO.5
10 24 71.8tO.3 6.7±0,8 21.5t2 .6 2.6i O./,
.0
"
74.H O.7 12.0:tO,J 13.8i O.6 .H. B O.'J
100
"
S6,HO.3 27. 110. 1 16JtO.:! S.'l!O A
0 4S 70.Si O.1) ·Uio.:! 25.2! 0.') H.'Hfl.6
10 4S 62.5tO.7 17.3i O. 1 20,210.6 7.51;0.4
50 4S 64.4t l.3 25.1±O.S OJ .H II'" '1,I1U.')
100 4S 40.2i O.6 5.0i 1.5 S4,StO.S 26.5i O.S
The results are the mean ± SO of three experiments.
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fi g. 3.28 (Pan)
DNA conte nt histogram of HcpG2 cells treated with different co ncentrations o fl ovasta tin.
77
E F
LOVASTATIN 1O!'M
M1= 4.9%
a:
W
In
==::l
Z
-l G H
-l
W
U LOVASTATIN50"" LOVASTATIN 10O!'M
M1= 27.3% M1=8.7%
DNA CONTENT
Fig. 3.28 (Continue)
DNA content histogram of HepG2 cells treated withdifferent concentrations oflovastatiu.
HepG2 cells were incubated with 10, SOand loa J.lM lovastatin for 24 and 48 hours and
were analyzed for relative DNA content by flow cytomctry. The cultures received no
treatmeut (control A and E), or were treated with 10, 50 and 100 11M lovastatin for 24
hours (8, C and D) and for 48 hours (F, G and H). The percentage of cells with reduced
DNA content due to apoptosis arc presented in the MI region.
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Fig. 3.29 (Part)
DNAcontent histogram ofHepG2 cells treated witb0.8 roMONBSA and different
concemrations of'Icvastatln.
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Fig. 3.29 (Continue)
DNAcontent histogramof HepG2 cellstreated with 0.8 mM ONBSA and different
concentrations of lovast atin .
HepG2 cellswere incubated wilh0.8 mM ONB SA inaddition to 10. 50 and 100 11M
lovastatin for 24 and 48 hours and were analyzedfor relative DNA content by flow
cytcmetry The cultures received 0.8 mMONaSA (0.8 mMONaSA A and E). or were
treated with 10, 50 and 100 pM lovastalin wit h 0.8 mMONBSA for 24 hours (8 , C and
D) and fOT 48 hours (F, G and H). 11Ie percentage of cells with reduced DNA co ntent du e
10 epoptcsls are presented in the MI region.
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of S phase cells after 48 hours. which was the same time when cells appeared with
arrested 01 cells. This suggests that the late S phase cells may be the subpopulation of
cells undergo ing cell arrest rapidly following exposure to lovasratin. These cells were
probably in early S phase ut the time they were incubated with tovastatin.
With exposure of HepG2 cells for 24 hours with 50 IlM lc vastatin, cells began to
uppcur with DNA content of less than 01. There was an increase in the cells entering S
phase and decrease in G2/M. which suggested the occurrence of a transient G I arrest. By
4X hours. the GI arrest was evident with relative increase in apoptotic cells in the
hypodiploidy region. further decrease in GUM and almost no change in S phase. These
observations suggest that the cells were arrested in the OilS phase and with extended time
the number of 02 arrested cells gradually decreased at the same time that cells appeared
with DNA content less than GI (MI region).
In 1-lcpG2 treated cells at 24 hours with 100 ~tM there was ,1 massive increase in
hypodiploidy (Ml%) with decrease in the 0 1 phase and concomitant increase in the S and
G2/M phases, indicating an arrest in the S-02 phase with increase in the proportion of
hyperdiploid cells(Figure 3.28 D). The continuous loss of cells in GI and arrest of the
cells ill the late S phase and 02 mitosis could be seen at 48 hours but with much higher
cells in S phase and less cells in 02l!vl ami with increase in the hyperdiploid cells (Figure
3.28 Ill . The percentage of apoptotic cel ls in MI region was dramatically decreased. The
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majo rity of cells whic h did no t undergo apoptosls beca me arres ted in the S·01 phase and.
with extended lime. the number of 01 arrested cells gradually decreased without
reenteri ng the norm al cell cycle .
3....2 Effects of lovastatln lind oleic acid
Cells treated with 0.8 11MONBSA alone after 24 hours unly showe d increase in
the GYM (Tab le 3.4). Con tinuous incuba tion for 48 hours showed an increase in thc
hypod iploid cells and almost no change from the 14 hours cycle.
The add ition of 10. 50. and 100 J.lM lovastatin to OAIBSA tor 24 hours showed
almost the same behavio ur as with lovastatin alone excep t upop totic cells appcurcd with
50 11M. simila r to exposure to 50 )-lM lovasmin alone for 48 hou rs. Also. exposure ttl
100 11Mlovastat iu with ONBSA show ed an increase in S-phase ce lls and decrease in the
GIM phases as co mpnred to the con tro l cells which is sirnifur10 the ce ll cycle utter 411
ho urs with lovas tatin alone at the sumc concentra tion.
By 48 hours, expos ure to 10 and 50 11M showed cells decr ease in the (f l phase.
increase in S phase, and G2/M as compared to contro l hut to dill cr ing degree. The
decrease in 01 was almost the same in both concent rations. The Increase in S ptmsc in
50 J.!Mwas muc h more than in 10 11M.and the dec rease in G2/M was much !l:ss than
con trol. Hyperdiploid cells co uld be seen in each histogram. Th e perccntugc of upoptotic
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celts was arou nd the same as lor the contro l.
Extended incubation with 100 ~lM lovastatin for 4X hours resulted in DNA
fragme ntatio n. The DN,\ cel l cycle distribution \\ :IS nu lunger llctcc tahlc: as shown ill
(Figure 3 .~9 H).
3.5 Lip id Metabolism
The lewis of triacylglyccrol. cholcs tcryl este r. aro B. mill upu A w'ere measured
following 0.8 mM ONI3St\ 10 investig ate the effects of Iovnsnuin lin synthesis uud
secretion of the major lipid fractio n in rnaritionally- supplc mcmcd cells . Altl luugh the rrcc
ratty acid to albumin mole rat io used was unphysiologically high. this a llnwell the
add ition of the smalles t amount of albumin and least volume while st ill del ivering
adeq uate free fatty acid (Ellswo rth ct al.. 1986). The usc of medium containin g oleic
tlcidiBSA un HcpG2 cells. should fac ilitate the synthes is and fornunlon nf Aptln,
cholestero l, cholesrery l ester, and triglyceride lind dcmonstnuc the effec ts or lovastutin
lipid metabolism (Pollinger et al., 1989: Cian llone cr al.. ]1)1)0).
3.5.1 Effects of levastat ln and oleic acidlBSA on synthesis :md sccretlnn of
cholcsterot and chotesrcryl ester.
For qua ntitative assay of lipids within cells and in the culture med ium. extracts
were separ ated by TLC. the chclcstcryl ester spot was visuullzcd with iodine vapour, und
scraped off. Three independent methods were used for quantitation:
radiometric using.a I'·q-oleic acid dilution method.
gas chromatography/mass spectroscopy.
spectrophotometric analysis following de rivitiza tion with o- phthaldehyde.
Figures 3.30 and 3.3I show a dose-response relationship between lovastann and
hnlh int race llula r end extracellular cholcs tcry l ester concentrations as assayed by the
radiometric method. With I~M lovastc un in the culture medium the endogenous
cholcstcryl ester decreased by 70 ± 3.5% (p < 0.0025) and the extracellular cholesteryl
ester hy 65 ± 7% (p < 0.000 1). both relative to the control cultures (The actual control
values were 147 ± 3.1 and 94.7 ± 6.3 nmol/mg protein within cells and in the medium.
res pec tively ). No funher decreases in cholesteryl ester were noted when the lovastarin
concentration was increased above I ~M. indicating that endogenouscholesterol synthesis
undsecretion into the medium had been completely suppressed. Comparing radiometry.
(i(,,/MS and spectroscopy: all three methods gave essentially Ihesame results (Table 3.5).
Cholesterol inhibitions by lovastctin which are also shown in the table almost parallel
cholcstryl ester.
3.5.2 Erfects of Invastattn and oleic acidIBSA on synthesis and secretion of
tr iacylp;lyccrols.
Friacylglycerols were determined radiometrically by a [ I~CJ dilution method
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Fig.3.30. Effect oflovastatin onsecretion of lipids into the
extracellular medium
Cells were incubatedwith 0- 2.5 IJ,M lovastatin in 0.8 mM [l4C] OAIBSAfor
24 hours. The results were the ave rage of I0 experiments . Medium (14C]
triglycerides and chol est eryl es ter exp ressed as percentage ofcont rol:l::SO .
The basal concentration for triglyceride was41.7 ± 2.8 nmol/mgcell protein
and for cho lesteryl ester was 94 .7 ± 6.3 nmol/rng cell pro tein.
a P < O.OOS
b P<O,OOI
c P < 0.0001
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Fig.3.31. Effectof lovastatinon HepG2intracellular lipidsynthesis.
Cellswere incubatedwith O· 2.5~ lovastatinin 0.8 mM[He) OAlBSAfor 24
hours. The results weretheaverageorlO experiments. Cellular p.e) triglycerides
andcbolesteryl esterexpressed aspercentageofcontrole SD. The basal
concentration for triglyceridewas294.3± 10.1 nmoUrngcell proteinand for
chclesteryl esterwas 147.3 ± 3.1nmoUmgcell protein.
e P<O.OOs
b P <O ,0025
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~Table 3.5 Comparison between HepG2 cell cholesterol and cholestery l ester, cellular and
extracellular, as measured by three different methods after treatment with lovasunin.
Trealment [" Cl MSlGC lI-phlhalaldehyde
Cells Med Ce lls M", csu, M.'
ce. CE Ch. CE Ch CE Ch CE Ch CE C h.CE
O.8m M 6 5.S 147.3 :52.6 94.7 89.3 178.6 6S.9 119.9 73.8 174.8
OAlBSC %3.3 %3.1 :t2 .5 :1:6.2 :1:5.1 :1:2.3 :1:82 :1:7.8 :1:5.4 14.0
OSi' M 28.8 66.7 26 .2 4 2.9 60 .7 120 .8 43.8 70,4 47.3 111.0
Lovastalin :1:6.6 :l:S.5 14.6 :1:8.5 14.9 :1:6.7 :1:2.4 16.3 :1:5.2 14.7
1.0l' M 2 l.S S4,4 19.1 33.4 50.9 68.8 20 .7 42.4 31.9 638
Lovastatln t7 .9 tS.8 :1:6.1 :1:6.1 t4.4 :1:1.2 :1:6.2 12 .7 .:1: 7.3 13.9
HepG2 cd ls wer<: incubated with lcvastatin in 0.8 mM OAISSA for H hours. Cholesterol (Ch) and
cholesteryl ester (eE ) content were determined by the appropria te method as described in experimental
procedures. The results reported as the mean ±SD runoUmg cell protein of at least 6 different experiments.
(Figures 3.30 and 3.3 /). The effect oflovastatin on triucylglycerol synthesisand secretion
over lhis wnge of concentrations was observed. In the absence of lovnstatin, intracellular
triucylgfyccrol levels were 294.3 ± 10.1 nmul/mg cell protein. but were decreased by
25.5% {p < 0.0( 25) in the presence of 111M lovastatin. No further decrease of
intracellular triacylglycerol levels was observed if the lovastntin concentration was
increased beyo nd I~lM . However, lor secretion of trincylglycerols into the medium the
response to lovastutin was different: at I 11M lovastcrin the decrease from control values
(4 1.7 ± :l.R nmollmg protein) was 45% (p c 0.00 1) and at 2.5 ~lM lovastatin the decrease
was 63% (p c 0.000 l) . The intracellular synthesis of triacylglycemls was much less
responsive to inhibition by lovasmin than is that of cholesreryl esters. A very interesting
observation is that at 0.5 11M lovastatin. triacylglyccrol synthesis is apparently increased.
l'hc trincylglycerol concentrations, relative to controls. were 1[7% (p < 0.005) and 134%
(p -c O.OUS) in the cells and in the medium. respectively.
.:t6 [ ffcet of Lovastarln on the Secretion of Apolipoprolcins A and B.
Culture medium recovered from 24 hour incubation of HepG:!cells supplemented
with 0.8 mM oleic acid/BSA and 0·2 .5 11M lovastatin was assayed for epolipoprcrein-A
(upo-A) and upolipoprc tcin-B (ape -B). Control values for cells cultured with oleic
"cidll3SA were: 18.4 ± 2.7 llglmg cell protein for ape-A; 10.5 ± 1.5 llg!mg cell protein
for upo-B.
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In the case of medium unsupplemcmc-d with oleic "dJln Si\. lovasta tin had n.l
eIT\."Ct on apoB and apoA secretion. the corarol lewis of upo-A and ilpo-B were 17.45 J:
:!.3 ~lglmg cell protein an<.l 3.6 ± 1.6 j.lglml,:cel l protein. f'\.-sp.., '. ·Iy. Additillll of 1.5
~lM lovastarin hat!minimal eITC\::t: 17.7~ . Iglmg for apo-A and 3.X:!:.:!. 1 pglm g ~\: lIl'hlte; n
for apo-B. Different sets of subculture experiment were used 10 comper e values ami
express the results as percent of control ( with 0.8 mM OtVllSA without llwlL"lalin),
Figure 3.3 :! shows the effect of lovnsuui n on :lpo·B secr etion in . mcdium
supplemented with O.8mM ONBSA over a range o f lovusta rin concentrations utter 24
hours exposure. The control apo-B concentration was 10.51 :I: :!.Kfl ~Iglmg cell prutein
and decreased to 9.84 - 6.99 I1gfmg cell protein with lovastatin conccmmnons u.I -2 .5
11""1. respectively. The signitlcant reduction in apo-B into the medium is associated with
the dramatic decline in chnlesteryl ester synthesis le. I 11M lovesactin, 31.7"1. less :Ipn·n
(I' -c0.05) and 7()oJ. decrease in chclesteryl ester (I' c 0.(025).
There was no significant effect on apo-A secretion. '11e ilptl·A cnntrol
concentration was 18,4 ± 2.7 .Igfmg cell protein and it was IK.79 - 211.111 ~ l glmg cell
protein exposed to lovcstatin (0.1 -2.5 ~IM).
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Fig. 3.32. Effect of lovastatin on HepG2 apolipoprotein accumulation.
Cells were incubated with0·2.5 J.lM lovastatin in 0.8 mM [L4C)OAIBSA for 24
hours. The results were the average 0£6experiments. Culture medium ape Aand
ape B levels were expressed as percentage of control", SO. The basal concentration
for Apo A was 18.4 ± 3.7 Ilg/mgcell protein and for Apc B was 10.5 ± 2.8ll g /mg
cell protein.
• P < O.05
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CIIAl'TElt 4
D1SCUS'SION
9 1
Cultured human IJcpG2 cells were used to investigate the acute andchronic effects
Ill' thedrug lovastatin, which is usedclinically to treat hypercholesterolemia. Lovastatin
is importantclinically because it is an effective inhibitor of l lMG·CoA reductase. the rate-
lirni tin~ enzy me in t~ biosynthes is of' chclesterot. The immediate product ofHMG-CoA
n..-ductase is mc valonatc, a key subsmncc not only in cholesterol biosynthesis but also in
posnranslationel modification of protein by prcnylalion.
Thc investigations reported here highlight the cytotoxic effect of HMG-CoA
reductase inhibition by lcvnstntin on the cultured human hepatoma cell line. HepG2.
Previous studies on lovastarin toxicity with cultured human cells used either a
pheochro mocytoma cell line. PC· 12. {Merom et al.. 1994) or an enterocyte line. CaCo-2
(Ilcrolu ct al., 1995). As liver cells inculture might behave differently becauselovastatin.
us used clinically. is a pro-drug requiring prior liver metabolism. it was decided to
investigate till:effects of lovastatin on a hepatomacell line.
"n tis investigation focusedon the toxic effects of lovastatin at exposure levels at
and above those currently used clinically. The laboratory approaches used ir:c1uded
electron microscopyand cell cycleanalysis by nowcytometry, investigation of peripheral
cell damage by enzyme and 0111l:r protein studies. and analysis of intracellular and
extracellular lipids at various exposure concentrations and times. The experiments were
also extended 10 consider the effects of supplementation of cell cultures with oleic acid.
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The findings are discusse d in light of current undcrsmnding (111 the sig ni flcuncc Il l' protciu
prenylatlo n on tile celt cycle and the mechanisms of ccll dcuth hy necrosis and apoptosi s.
To determine the acute and chronic toxicity Ill' lovustatin III IkpU~ cells . a cell
survi va l study was conduct ed using two diffe rent analytical approaches. the SR B test and
LDl-llcakage. It "'>IS found that 50 ~l M . but not tower. concentrat ions of lovastmin in the
cultu re medium markedl y decreased survival uf'tcran exposure ofouly 14 hour s ((1=(1.\);)
The lower lovasratin co ncentrations used in this study (0 .1 • :!.5 ~lM) did no t kill celts ,
even after exposure for 8 days. But after ~.J days, cells cultured al tovasuntn
concentrations of 5 and 10 p M showed a significant decrease in viability as compared til
contro l specially in the first three days (a=O.05).
Albumin is generally considered 10 have nine hig h-affiuhy b ind i n~ sil\.:S for oleic
acid. Moberly 1.'1nl. (1990) were unable to detect cytotoxic ity to IkpGl cells with up to
1.0 mM oleic acid at a 9: I molar ratio of oleic addJ llSA. Cell durnugc was assessed by
LDH release into the culture medium or by cha nges in ce ll proteins . The uhscncc or
observab le cyto toxicity of fatty acids on cultured lIcp02 cel ls was also re ported hy
Ellsworth et al .(l986). On the basis of these two reports that (I.X mM oleic ucid in a
saturated complex with albumin docs nol cause cell death and is withinthc physiologica l
free fatty acid range for human serum. th is concentra tion was chosen I'm the experiments
reported in this invest igation.
It W'dS not anticipated that oleic acid/BSA woutd engender <lny significant
eynnnxicity as a nutritional supplement and it was found. in agreement with the cctbcrs
cited above. rbat LDIl Ic:Jkagcand intracellular protein content were normal for the first
24 huurs. On the other hand, the degree of ALT and AST release and the morphological
changes suggested slrongly that pathological changes had been initiated.
In addition. if cell cuilures containing otherwise nontoxic lovastatin concentrations
were supplemented whh o'eic acid/BSA. cell viability was significantly reduced at all
lovnsraun concentrations (a -O.05); Oleic acid and lovastatin act synergistically in their
cytotoxic ef fects. It has been shown (McKenney et al.• 1995) in clinical studies that
dietary fat enhances the bionvnllability of lcvastatin, Patients ",'hose blood cholesterol
levels were reduced with lovastatin and a low fat diet experienced an additional reduction
in levels when they increased their intake of fats. It did not matter if the supplementary
fats were saturated or unsaturated. This observation was explained by either increased
availability o f jovastarin due to coadministration of fats or by lovastatin promoting up-
regulation o f I.OL receptor symhesis, These findings are interesting in light of 3D
observation in rats (Skcmedal et al.• 1994) that enhancement of diets with lipids caused
increased osmot ic erythrocyte fragililYand heart muscle response 10 catecholamines. When
lovasreun was coadminisrered the effects of a high -fat diet were enhanced. These effects
n]' tovnsrmin were dependent IIpon the type of dietary fat as they were prevented by the
presence of cod liver oil. Our dutn showed that in addition to lipid reduction. in the
presence l, r oleic <1ddl BSA the cytotoxicity (, I' lll\':lsiotin W,I:- increased. lacs c
observations can best be explained by S\lggcsling that oleic add acts as a currier w hidl'
for lovas tnrin. or vice-versa. The cl inica l sig nif'icuncc of this l'xpbml til' lI is lhat lhe
hepatic uptake of the drug is dependent on adequate serum lipid revels: this includes. or
course, nor only the clinical efficacy of the drug but alsocytotoxic effects.
The presence of AST and ALT in the medium is indicat ivc Ill' cclllcukugc. These
enzymes were detected utter 24 hours in oleic m:idlBSA-frl.'c medium with 10 11M
lovnstatin. or with oleic acid/BSA alone. Even control cells were dcmonstrntcd to he
leaking AST and ALT by tile sixth day. These two enzymes were found to he more
sensitive early Indicators of plasma mem brane damage than the SR B test hut less sensitive
than LDH after 24 hours (u =O.05). But. after three Jays the situation became reversed:
AST and ALT leakageprovided a clearer indication of cellular damage than t.Dllleakagc
(p < 0.0001).
Morph ologic eviden ce of lovastatin toxicity was assessed by transmission electron
microscopy. Exposure of HepG2 cells to lovastatin resulted in the development Ill' a
variety of morphologic alterations with two distinct endpoints. namely necrosis und
apoprosts. A complex pattern of changes involving cell membrane, organelles. cytosol
and nuclear chromatin was observed. This spectrum of ultrastructural abnormalities
started with simple cellular swelling and ended with franknecrosis with loss of cellular
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structura l details. The earliest effects were produced by a Lday exposure to 2.5 ....M of
lovasrarin alone. The magnitude of these changes was bothdose- and time-dependent.
Abnormalities n:sultinll from exposures for less than 6 days to SOJ.lMor for 2 days to
Ino JlM tovastaun were mostly limited to the mitochondria. rough endoplasmic reticulum
und cytosol. Toxic degeneration to this extent is probably reversible (Cui er al., 1995).
Frank nec rosis as indicated by complete disruption of cell membrane, chromatin d umping
und loss of structural details was produced by exposure to SO lJM lovastatin alone for 6
days. Although necrosis also resulted from exposure to 100 ~lM lovastatin for 1·2 days.
it was noted that longer exposures to this relatively high concentration did not necessarily
increase the proportion of necrotic ce lls. Studies have shown that many cytotoxic agents
"tnrgct" cells in the late 02 and M phases since the interphase cells (S phase) are
gl'tll..'rally resistant (Reipcrt cr el., 1995). If Ihis principle applies to lovastatin-induced
cytotoxici ty, susceptibility would not be universal 10 311 tested cells. but would rather be
limited to those in the G2IM phase. This hypothesis may provide an explanation fer the
obscrvaric n that longer exposure to I00 ~lM lovastatin did not result in increased necrosis.
S upplementing the cultures with 0.8 mM oleic acid/BSA boosted the extent of
locasratin-induced morphological damage. Cells incubated with oleic acid, even in the
absence of lovestattn. showed mild degenerative changes after 24 hours. Morphologic
changes produced by a 24· hour cvposute to 100 lJM lovastatin and 0.8 mM oleic
:LcidlI3SA were similar to those resulted from the exposure 10 the same conce ntration of
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lovestat ln alone for 2-3 days.
In apcptosis. also referred to as programmed cell death. fmgmcuta tion of DNA
occurs under the effect of calcium-depe ndent cudonuclcascs (Uu.ill cr al.. It}!)); Bnrbicru
et al., 1995). This active process specifically targets nuclear chromatin where it pnll luces
characte ristic morphologic changes. Unlike other co nventional mechanis ms of cctl dcuth.
apoptcsis is not initiated by alterations in the cell membrane permeability or cel l
respiration . According ly, apoptotic cells exhibi t character istic conde nsation or rho
chromatin in tight apposition to the nuclear membrane with relatively preserved integrity
of the cell membrane (Lizard et ul., 1995). Organelles. particularly mitocho ndria, arc
genera lly preserved. Apoptosis is also char acterized by a loss of mitochondrial function.
It has been reported thai mi tochond ria may have an important ro le in regulating apoptosis
(Vayssicre et ul., 1994; Reipert cr al., 1995). These features represent the basis for the
morp hologic distinction o f apoptosis from necrosis by electron microsco py. Since the key
mechanism of necrosis is cell membrane damage, necrotic cells tend to exhibit cell
mem brane disruption. mitocho ndrial derangement and other organelle damagc as desc ribed
earlie r.
Indications of apoptosis started to ap pear with 50 ~lM lovasuuin after a 24· htlur
expos ure. and fully developed apoptotic bodies were seen afte r 6 days. It was also noted
that the degree ofapoptosis seen by electron microscopy after a e-duy exposure to 50 '1M
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lnvastatin was comparable to that of a 24-48-hour exposure to 100 11M. II is concluded
thai the ability of lcvastarin 10 induce apoptosis is both dose- and time-dependent. This
aspect uf lovastatin toxicity on J-lepG2 cells was similar 10 its necrosis-inducing capacity
discussed curlier. It is nolewonhy that with longer exposure lime (> 48 hours) to 100
J-I-M lovasratin alone. not many apoptctic bodies were seen. In \ ';' 0 studies of
chemot herapeutic agents that arc purely cytotoxic reported similar results (Zaleskis er a l.•
11J'14). Apoptosis was shown to be a time-dependen t phenomenon that disappears at high
concentrations of the drug. It was suggested that relatively high drug concentrations
applied over extended pcriods of time probably produces necrosis vin different metabolic
mechanisms and overrides apoptotic processes (Zaleskls et nl, 1994; Ormerod et al.•
199-1). This characteristic 48-hour response to 50 or 100 pM lovastatin was achieved
within 24 hours in the presence of 0.8 mM oleic acidlBSA. Exposure for longer intervals
10 lovasta tin in rhe presence of 0.8 mM oleic addlBSA probably hada higher necrotic
cffcct iba t eliminalerdcells before apoptosis could beinduced. Apoptolic bodies that were
formed at ear lier stages of the exposure most likely disintegrated and become
inconspicuous when the sample was examined after a 4-6 day exposure 10 100 J-i- M
lovastatin .
When not dividing or preparing for division. cells arc in a quiescent state known
us GO. When a cell is actively engaged in the act of mitosis. the stage is known as M.
Prolife rating cells progress through a sequence of several phases as they progress from
9.
GO to M. These phases are referred to as G I. S. am.!G2.
During Gl. a cd l undergoes RNA and protein symhcsis, As DNA hils 1"1111
replicated. G I cells can not bedist inguished from GOcella on rbc basis of DNA comcor.
At the beginning of S phase.a diploid cell contains 1\\"0 copies of each chromosome t2Nl
and by the end of the S phase this has doubled (4N). TI"II: ti lllllwinl:t01 phase is the
period of RNA and protein synthesis in prepara tion lor mitosis and cell division
(cytok inesis). The mitotic M phase is usually so short that cells in this phase cnnuo t he
distinguished from G2 phase cells on the basis o f DNA content. since both nrc -IN. The
process rap idly proceeds to cytokin esis and the resulting d:lllghler cells have reestablished
the d iploid karyotype. They can continue for one or more cycles of replication , or reenter
the GO rest ing state for indefinite periods.
As discussed previously. the percentage of cells in ccch stage of the cell cycle in
a mixed population of dividing cells can bedetermined efficiently by Ilow cyromctry; a
techniq ue which labels DNA with a fluorescent dye and analyses the relative flu orescenc e,
and thus the DNA content, of individua l cells as; they arc caused to pass acros.s a detector.
The value of flow cytcmetry , that it can analyze the DNA content of individual celts. is
also its limit ation because il cannot di stinguish between stages in the cell cycle that slnue
the same DNA/cytop lasm ratio.
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The normal DNA his togram generated by !low cytometry is characte rized by a
do minant (Gl Lpeak, a second smaller (G2/M) peak, and a lowS phase lying betwee n the
GI and the GUM peaks (Zarbo, 1994). Flow cytometry canalso detect ce lls containing
less than the normal diploid DNA content (subdiploid: M I): the presence o f such ce lls is,
us wilt be discussed below. characteristic of cel ls undergoing npoptotic DNA degradation
(Atc n cl ul., 19(5). Flowcyromeuy a lso detects hyperdiploid cells that con tain amounts
or DNA in excess o f ihe normal 4N typical of S phase cells.
Dete rmination of the percentage of cells in eac h phase is an important ke y to
understand ing the b iologyand underlying biochemistry of celt replication; particularly if
the analysis is coupled with experimen tal treatment of dividing celts with drugs that act
us specific inhibitors of mitosis and ce ll divisio n (Ormerod 1990; Keren et al., 1994).
Such analyses permi t the elucidation of bioc hemica l processes responsible for cell
replication, particularly in the case of drugs such tIS lovas tatin tha t act on specific stages
within the c ell cycle. This approachcarries the potential of identifying cell-cycle-specific
inhibitors th at may be of use in the manageme nt of cancer .
In gene ral, cu lturedcells treated with toxic levels nflovastatin are arrested at stage
G I in the cell cycle and as ce ll death occurs by apoptosis a subdip loid peak is gene rated
[N icoletti ct nl., 199 1; Jones and Lafrenz. 1992).
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Flowcyto meuy wasused to study the effect of lovnstatinon cultured H~p(l2 ce lls
at exposure levels of 10, 50, and 100~IM: and with 2~ and 48 hour incubation periods.
High numbers of frankly apoptotlc cells were only seen with IUO111\..1 lovasuuin.
Aller 24 hours incubation. subdiploid ce lls represented 5 1.1% til' the tetul population .
This correspond ed to the percentageor dead cells estimated by the S[Ultest (5l'i.1)% ) .
Electron microscopicexamination of these cellscon firmed the presence of lllorphllllgica l
features of ap optosls: cell membrane blcbbing, chr omatin aggregation, and densely-
staining cytoplasm. In addition to the high proporti on of subdiploid (MI) cells. tILe
percentage of cells in S phase was almost doubled and that orG2/ M was almost 17%,
higher. relative to the controls. Decrease in Gl ce lls with increase in upnptctic cells in
sub-G ! and a concom itant increase of S and G YM ha ve been reported elsewhe re
(Gorczy ca et nl., 1993; Hiranoet nl., 1995a: Shiff ct al., 19(6 ). The gcncrnl conclusion
is that cells treated with 100 11Mlovnstmin for 24 hours we re only undergoing upoptosis
and that necros is was insignificant.
After 48 hours of incubation, e lectron m icroscopy showed that most of the
characteristic features seen after 24 hours with [00 11M Iov astatin had disappeared. By
this time the c haracteristic feature was necrosis rat her than upoptosis. However. som e
apparently normal diploid cells remained intact. as demonstratedby the flow cytomctry
histogram, which also showed that the disrriburion of cells in the cell cycle was
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significuntly differen t from the contro ls. The MI peak after43 hours was 8.7%. This
was much lower in comparison with the 56% peak detected 24 hours earlier. The
occu rrence o f S phase arrest was confi rmed by the high peak (32.4%) as compared to
co ntrol (9.5% ). The G2/M peak was 25.7% compared wit h 34.2% for 24 ho urs and with
15.5% for the contro l. The absolute num ber of cells counted by trypan blue and SRB test
was very lo w , indicatingthat mas!of the cells had disintegrated .
Considering the results or 24 and 48 ho ur exposu re to 100 flM lovasa tin. it is
upparcnt thnt the majority of cells which didnot undergo apoptosis became arrested in the
Sand G2/M phases w ithin 24 hours. With exte nded exposure time, thenumber of G2/M·
arres ted ce lls gradua lly decreased. G2 arres t prior to cell death has been repo rted
else where (Sorry et al., 1993 ; Enoch and Nor bury, 1995). Both studies reported that
delay ed cel l dealh w ith DNA degradation may be due to apoptos is.
The results w ith electron microscopy co n lirm tha t there is more tha n one type of
cel l death ta k ingplace: apoptos isand necrosis ar e evident. In rat liver, inductionof both
apopt osis a nd necros is has been described for hepatotoxic ag ents in vim {Ledda-
Columbano ct al., 1991) and in cultured T cells by mercuric chlo ride (Aten et al., 199 5).
1\ significant proportion ofthe ce lls remained res istant to apo ptosis aft er 48 hours.
This could be explained by ce ll arrest in the S-phase. T he apoptosis-inducing effect of
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lovastatin wasmos t pronounced in Gl andleas t pronounced in the S phase. lt cou ldniso
bedue to increase of mitochon drial number as a positive adaptive response 10toxic ugcnrs
(Reipert et al., 1995). Increasein mirocbondrial num bers did ncr occur whencclIs lI'erc
grown at low lova statin cc nccnnntions,
A poprosis started wi thin the First 2:4 hourso f lnculmuon:1110 hy -III hours Ihe
npoptotic cells had either d islmcgrated. floated tothe surface of theculture medi um,or
become necrotic. Necrotic cells wen: readily identified byclccconrn tcroscopy. which
demonstrated the p resence of a mixed populat ionof apc ptotieand necrotic cells un cr 411
hours inc ubation. It hasbee n shownthatcells maintain the typlca! ilpllp tot ic I\mrphulll~Y
for only a short period of time and then undergo secondary necrosis if they escape
phagocytosis (Bom er ct nl., 1995; Wyllie ct al., 1980 : Majno and Juris. 1(95).
With 50).1M lovasta tin for24 hours.the MI component was1).8% uud U2/ M had
decreased by 26% relative to the controls,a Findingwh ich was consistent with th e SitU
test (23% celldeath). Electron microscopy showell changes in cell mcm hranes and very
emly indicationof apoptosi s. Either cell death was ta king place in the G2IM phase. a
phenomenon that has been observed in other similar studies (Feurnhcad et al., 11)!)4:
Engelke and Hacker, 1994; Pillman 0.'1 ul., 1994; Borner ct al. , 1995: Sriknnt, ICJl)5;
Barbiero e t 01., 19 95); or th e cellswere arrested al G2/M (Barry ct al., lCJcJ3).
103
With 4&hours ofincu bation with 50 J.IM tovesraun, theproportion of apoptotic cells
was ]5. 5 % as de te rmined by now cjtometry , electro n microscopy. and theSRB res: all
three ap proaches giving e~nl ill lly the same resu lt . Compaml with 24 ho urs. the
proponion orcd ls in the G I pbcsc peakbad lneeascd . theS phasewas unchanged. and
GYM ce lls decreased by 5 0%.
Treatmen t with10 JlM lovas tatin for 24 hoursd id not induce cell death. However.
the S phase peak was lWO times greater than th e contro l. This indicated that the cells had
become a rrested in theeel! cycleafter DNA replication butbefore mitosis. 01 ce ll arrest
W;15evide nt with 10 flM lo vasuln for 48 hours. Flow cytome try analysis showed an MI
o r 4.9%. Drber studieshav e shown that ce ll arrest in Inc G I phase is characteristic of
lovastati n to ~ ic i ty towards cultured normal o r tumour cells (Engelekeand Hacke r. 1994;
Borner ct al., 199 5; Reedq uisi et 011., 1995).
Th e apcptc sis-resistant phenotypeof Hep02ee lIs inS phaseand G2IMmos t likely
explains the rela tively g reater ce ll surviva l at 100 J1M lo vasarin upon pro longed
inc ubation . At lower concemraticns apoptos is resistan ce was a lso seen but with d ifferent
cell cycl e phases and incubation times. The ce lls Ih,1( became apoptoti e were
pred ominantly rrom the G I . and to a lesserextent rrom theG21M phase. of the cell cycle.
It is a va lid genera lizationtha uhe transition to apoptos is happened when cells were inthe
quiescent phaseo f the cell cycle.
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Three populations of pathological cells were seen: n..x rutic cctls: cycling. pre-
apcptoric cells; and cell s blocked in the G2JM phase. The rel;ltivc incrc-asc in the
proportion of Ml celts and the apparent stabiliz..ntion of cell viability can beexplained hy
the concomitant presence of two populations of cells: one pop uhuion W'L~ uying ;UlU the
other dividing.
The findingsof this investigation arc strongly consistent withthe premise that cuch
lime a group of cells progressed through the G2/M phase it proportio n would become
arrested and the remainder would proceed through another division cycle. Thus. the
uumber of apoptotic ce lls II any given time would depend on the balance between the mtc
of their appearance and rate of the ir loss. ln other words, if the rate of induction Ilf
apoptosis was lower tha n the .atc ofdisintegration of npcproric cells. then few(If the latter
would be observed; or vice-versa. In practice. npoptotic cells were sufficiently stable 10
permit their observation after 24 hours with 100 j.lMlovastntin , or 48 hours with 50 ~tM
lovastatin.
This explanation is equally applicable to cells incubated with lovastutin lind n.1I
mM o leic acid/BSA but the presence ~f oleic acid advanced the appearance of abnormal
features to an extent corre sponding more-or-less to an additional incuba tion Il l' 24 hours
with lovastatin alone. For example with 100 IlM lovastntin and 0.11 mM oleic acicllBSA
and 24 hours incubation. the ind uced pathology was essentially similar to Ion 11M
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lovas tatin alone for 48 hours. However. less tetm inally-apc ptcdc cells {apo ptc tic bodies)
were detected by flow cyicmerry than by electron microsco py. Th is probably means thai
som e cells progresse d Ihrough ancihc r cell cycle before su ccumbing to apoptotic death.
as has been reponed in other studies (Barry cl al., 1993; Shiff et al., 1996).
For cell s treate d with 10 and 50 J.1 M lovastatin and oleic acidIBSA. the relative
increase of cell s enteri ng S phase from 24-48 hour s and the corre sponding decrease in
G2IM confirms the oc c urrence o fa tran sient Gl arre st. The majority of the cells whic h
did not undergo apoptosis became arrested in the 02 phase within 24 hours . With
exten ded incubation time the number of G2IM arre sted cells gradua lly decreased wilhout
ree nter ing the normal cell cycle. Following prolong ed incu bation necrosis became more
significant than apoptosi s: with 100 11Mlovaseratin DNA fra gmentat ion occurred and the
cell cycle distributio n was no longer detectable .
The rate of uia cylgly eerol, chclest eryl ester and apo B synthesis in cu ltured liver
cells is a funct ion of the fatty acid concentration in the medium (Rash et al. 198 1;
Bostro m et al. 1988 ; Cian flone et at 1990, Brissette and Falstrault, 1994).
Supple mentation of th e culture medium with 0.8 roM o leic ncidlBSA perm itted an
analysis of the effects of fatty acid nutritio nal enhancement on cholestero l. cholestery l
ester and triacylg1ycer o l synthes is and secretion by HepG 2 cells. The impact of lipi d
supp lementation on 3poB and A poA sec retion was also de te rmined . Since lovastatin is
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a strong inhibitor of primary cholesterol synthesis it " i ll alsoinhibit cholc:-1~'r)'1 ester iIIIlI
apo B production ind irectly (C ienflone ct al.. 19114). Oleicacid\ BSA \VOlS ;kkk."\l to Inc
cu lture medium in the expec ta tion tha t this would .."l\h.1.ncC'secreti o n of aflUliflllfll'\llci n n-
contain ing panicles : and so m :lb'llify the differences between control cuhurc-s and cultures
co ntaining lovastatin (Mober ly ~1. al., 1990; Cianflonc ct al.. 199 0.: Dixon c1 al.. Il)tl l) .
Lovcsuttn con centrati ons up to 2.5 pM were used because th is conc cmmtion runge
incl uded the serum levels achieved in normal clinical pract ice and has hecn shown in this
study not to engende r significant morp hological damage utter 24 hours. T he intmccllnlar
sy nthesis and extracellular sec retion of triacylg lyceto ls was mu ch less responsive io
in hibition by lovestctin tha n was that of cholesreryl esters, Irnraccllu lar ~'Yn thesis nf
tri acylglycerol and cholestery l ester were essentially independe n t. During experimental
interventions. levels of apo- B changed in concert with intrace llular and extracellular
cholestery l ester-andtriacylg lycercl. b ut intracellular lriacylglycer o l remained unchang.."I.1.
Apoli poprotein B (a po B) is thc major protein componen t of plasma VI.D L anti
L D L. 1ncreasedconee ntratia n or plas ma LDL cholesterol and apa B have been implicated
as risk factors for the developm ent o f atherosclerosis (S harrett ct al., 1994 ; Cnrmenc ct
nl., 1996). Exposure of Hep G 2 cells to aid e ucirJIBSA elevates intracellu lar chole sterol
levels , stimulotcs apoB secre tion and reduces receptor-mediated uptake o f LDr. ( Fuki ct
:II., 1989). Cianflone ct al. ( 1990) demonstrated that oleate st imulates "poll scc rcnon
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rromcultured 1-lepG2 cells an d that the effect was completely suppressed by simultaneous
incubation with lovesmun. As lovostadn inhibits cholesterol ester biosynthe~is, and
c holesterol ester biosynthes is is tightly coupled to the synthesis and sec retion o f apoB
(Ciantlone ct al., 1990), these observations imp ly that the stimulato ry ef fect of olea te on
a poll secre tion may in fact be due to enhanced cholestero l este r synthes is from oleate.
T hese ill vitro findi ngs appear to co mplement the exper imenta l observations o f Arad,
Ra makrishnan and G insberg (1990) who demonstrated that when patients with combined
hy pcrlipidacmia we re treated with lovasratin, their apoB producti on de creased but the
ca tabolic rate of the LDL opoB was unchanged. On the o ther hand , the work of
F urukawa and Hirano ( I993 j suggests that, for at leastshort -term incubation , experimental
modulation of choles teroleste r biosynthesis.wh ich was inhibited by Iluvastatin, does not
a lter apoB kinetics in HepG2 cells. These authors concl uded that rapid stimulation of
apcll secretion by oleate is not associated with cholesterol es ter biosyn thesis. Our
fin dings arc consistent with Ciantlonc and would suggest tha t the d iscrepancy with
Furukawa and Hirano could be the short period of incubation which they used (180
mi nutes) which would beinadequate for induction of morphologica l damage byOA/BSA.
Also. it is demonstrated that 24 hours of Incubation with I IlM lo vastatin wererequired
to demonstrate 70% suppressio nof cho lesteryl ester synthesis, but evenafter 24hours apo
Il synthesis was only suppre ssed by 31.7'10. Also, Furak nrna and Hirano used 0.4 mM
oleic "cid/BSA, half the conce ntration usedby Cianflone and in this presen t investigation.
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The safety of lovastatin fo r clinica l purposes is auributcd to its abili ty to block
cholesterol biosy nthesis at a concentrat ion thnris insufficient to inhihit protein prcnylnrion
signific antly (Sinensky ct al.. 199 0 ). The results presented in this repo rt dcmonumtcrhnt
even relatively high concentratio ns of lc vastntin are nut roxie to the well-dilfctcmiutc d
hepatoma cell line HepG2. It co uld be that their action on these proc esses arc linked to
the modulation of the rnevalonate pathway. This could odd another dinwnsiou til the
antiutherosclerotic properties of this drug. by providing a phnrmacoktgical tool to
understand the role of isoprenoids in th e modulation of cellular gr owth a nd hin l ll~y
(Corsini et al., 1995). Therefore this cell line is a convenient model for inve stigation of
mevaloneie-dcpendcnt cellular m echanis ms. However. this study dcmonsreucs that
prolonged exposure of ce lls to qu ite low concentra tions of lovastaun in eombtnnuon with
fatty acid can cause cell death.
It is concluded that below acutely- toxic lovnstadn concentrations. the resistance of
HepG2 cells 10 chronic exposure may be explained as a consequence o f the cel ls having
stopped dividing. Such dlvisicn-arrested ce lls would havereduceddemand for cholesterol
for membrane synthesis and the resi dual slow nux of mcvalonatc-dcnved iso prene units
diverted into no n-sterol branches of the mcvalcnate pathway such as essential protein
preny lations (Marom et al.,1994; Corsini et al., 1995). The findings LJf our study arc
consistent with suggestions (Buchwald. 1992) that lovastatin and other s imilar drugs have
utility in cancer chemotherapy as inhibitors of cell division, provide d thut the general
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cytotoxicity of this class of drugs could be overcome by selective targeting (Corsini er al.,
1995) . Targeting ml1JiglU1Ot cells by lcvastatin in speclflc segments of their progression
through the ':.c11 cycle, ouldpenni t the therapeutic induction of epoptcsis and the selective
deletion of undesirable cells.
Th ese results. taken together with clinical observations in the literature. confinn
the necessity for a stringent combination of drugs and diets for treatment of
hypercholesterolemia: a low dose of lovastatin with strict diet control would appear a safe
choice. Attempts to control hypercholesterolemia solely by drug intervention without
udequutc control o f dietary fat would necessitate much higher drug administration to
achieve an adequate level of serum cholesterol and might expose patients to the cytotoxic
effects of inhibited protein prenylation. such as we have derncnstrated in this study.
Although the observa.tions presented above are based on in vitro data. it is clear that
carefu l studies on the in vj,'fJchronic toxic side effects oflovastatin and other HMG-CoA
reductase inhibitors are required.
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CHAPTER 5
SUMMARY
III
The lower lovastatin concentrations used in this study (0.1 - 2.5 j.1M) do not kill
cells, even alter exposure for 8 days. However. if cell cultures containing
otherwise nontoxic lovasuuin concentratio ns are supplemented with oleic acid (as
lin oleic acitll bovine serum albumin complex). cellular morphology and function
arc dera nged and cell viability is significantly reduced.
2. The results of this work suggest thai cultured HepG2 cells provides a valuable
practical model to investiga te mevalonate-dependcnt cellular mechanisms; and also
us II general experimental system for ill vivo investigations o f cell death.
J. The cytotox icity of oleic acid on its O\VTI 1$ appare nt, Thus it is difficult to
consider this compound as simply a non-toxic nutritional supplement for long-term
cell culture . As lipids appe ar to act a! transcellular carriers for lovastatin. both the
clinical efficacy and any potential cytotoxic effects will be dependent on
nutritional status.
~ . Lovastarin-induced apcptos is is charac terized by an increase in mitocho ndrial
numbers and abnormal morphology . Lcvastutin-inducedapoptosis has poten tial
as a too l to investiga te the role of the mitochon drion in induction and regulation
o f upoprosis.
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5. This study has demonstrated thut npoptosis lind necrosis occur sequentially in
lovasunin-i nduced cell death over a prolonged period in lkpG2 cells. unlike other
systems where cell death takes place quickly. There fore. l lepG::!/ll1vastatin
provides a model to study the mechanism of cell death.
6. Cell death was shown to take place at a specific stage in the cell cyc le.
7. The results of this study on specific cytotoxic effects of luvnsrutin provide
experimental evidence in support of suggestions in the literature that I,wast.lti" . hy
virtue of Its effects on cholesterol-dependent processes in cell division.may have
a role in cancer therapy.
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